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Tuberculosis (TB) is a leading cause of morbidity and mortality globally. Scale-up 
of evidence-based interventions has had limited impact at the population level. 
Targeting interventions based on geographic and movement patterns may 
improve TB control. 
Objectives 
We use the spatiotemporal epidemiology of TB to identify populations at high risk 
for experiencing barriers to care and acquiring TB disease and consider the 
possible impact of geographically targeted interventions in urban sub-Saharan 
Africa.  
Methods 
We conducted a facility and community-based case-control study in Kampala, 
Uganda. We describe heterogeneity of zone-level TB notifications and assessed 
the potential impact of using programmatic data to target active case finding in 
areas with high TB burden. We then characterize geographic mobility patterns 
using latent class analysis and assess the association of mobility with TB disease 
using conditional logistic regression. Finally, we assessed the association 
between distance from home to health care facility on treatment outcomes 
among TB patients using multivariable Poisson regression. 
Results 
In our study area, 5 geographic zones constituting 22% of the population 
accounted for 62% (95% CI 47-75%) of facility-based TB notifications and 42% 
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(95% CI 35-51%) of undiagnosed TB in the community. A two class model of 
geographic mobility was largely driven by frequency (≥9 times per month [84% 
mobile vs. 2% non-mobile] and duration (≥6 hours [78% vs 17%]) of travel >3 km 
from residence; there was no association between mobility and TB case status 
(adjusted odds ratio 0.85 [95% CI 0.44-1.6]). TB patients residing ≥2 km from 
their treatment health facility were less likely to be lost to follow-up (adjusted risk 
ratio [aRR] 0.57 [95%CI 0.41-0.79]) but more likely to die prior to completing 
treatment (aRR 1.42 (95%CI 0.99-2.03)]. 
Conclusions 
Geographic targeting of active case finding interventions may be an efficient way 
to identify undiagnosed cases. Defining mobility is complex and further research 
is needed to understand mobility patterns and their association with health 
outcomes. Geographic barriers to care play a role in TB treatment outcomes. 
Spatiotemporal patterns are critical components to understanding the local 
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Tuberculosis (TB) is a major contributor to morbidity and mortality globally. 
Despite substantial international and local investment in the scale-up of evidence-based 
interventions, global progress in reducing TB incidence has been slow (1). TB control 
interventions targeted at specific high-risk populations have shown promise; however, 
challenges remain in identifying and reaching those populations. Building off the current 
evidence of spatial heterogeneity of TB burden globally, this research aims to 
investigate individual spatiotemporal (i.e., location and movement) patterns as potential 
risk factors for TB and to develop spatially targeted interventions for improving TB 
control in high-risk populations in urban sub-Saharan Africa. 
 
Epidemiology of Tuberculosis 
There were an estimated 10 million cases of TB resulting in 1.5 million deaths in 
2018, making TB the leading cause of mortality due to a single pathogen worldwide (1). 
The burden of TB is geographically heterogeneous; among 202 countries reporting data 
to the World Health Organization (WHO), TB rates range from <5 per 100,000 
population to upwards of 500 per 100,000 population (1). The majority of new TB cases 
are found in African (24%) and South-East Asian countries (44%) (1). 
The heterogeneity of TB disease is driven by risk factors that contribute to an 
individuals’ likelihood of developing TB disease. Risk factors for TB include those that 
biologically increase an individuals’ chance of disease by hindering the immune system 
response as well as factors that increase an individuals’ likelihood of being exposed to 
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TB. Globally, HIV is one of the most important individual drivers of the TB epidemic (1), 
particularly in sub-Saharan Africa where approximately a third of TB patients are 
infected with HIV (2,3). People living with HIV may be more than 20 times as likely to 
develop active TB upon exposure compared to those without HIV (4). Treatment with 
antiretroviral therapy (ART) reduces but does not eliminate this risk (5). Areas with high 
HIV notifications are associated with increased TB burden (6), and TB death rates are 
largely driven by HIV (3). In some settings (particularly in southern and eastern Africa), 
HIV is the primary driver of TB risk, such that scale-up of ART leads to a population-
level reduction in TB (7). Other individual risk factors that can increase risk of TB 
include diabetes (8–10), smoking (8,11), alcohol use (8,12), undernutrition (13), and 
exposure to indoor air pollution (14).  
In addition to individual factors that may limit an individual’s ability to control TB 
infection, the structural context contributes to TB risk; these factors range from distal 
factors such as government expenditures to more proximal factors such as individual 
living conditions (15). Structural determinants that increase risk for TB include 
urbanization, crowding, housing conditions, and demographic and economic trends 
(16). The structural context in which an individual lives is inextricably linked to social 
determinants that increase an individual’s risk for TB (17,18). Most notably, TB has long 
been known to be a disease of poverty (19), with effects stretching from national health 
expenditures (20) to individual unemployment (6). Additionally, overcrowding (21,22), 
poor housing conditions (23), and homelessness (24) can lead to conditions for TB 
transmission. These social determinants are often associated with individual additional 
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risk factors for TB (25) that act on a biological level and must be addressed in order to 
have a population-level impact on TB burden (26).  
 
Basis of TB Control 
TB is an caused by transmission of the Mycobacterium tuberculosis bacteria 
(27). Upon infection, an individual’s immune system may control the bacteria, resulting 
in an asymptomatic infection (latent tuberculosis infection [LTBI]); LTBI may reactivate 
and develop into active disease if an individual later becomes immunocompromised 
(28). Other individuals will immediately develop active TB disease. Only individuals with 
active TB are infectious (29) and while it is likely that coughing it the primary mechanism 
for transmitting TB (27), there is growing evidence of transmission of subclinical (active 
but asymptomatic) TB (30). Many TB control activities focus on understanding and 
preventing further transmission of TB (31); other strategies focus on preventing TB 
infection from reactivation of LTBI (32,33). In order to have an impact on TB, control 
efforts must both treat the existing cases as well as prevent future transmission, an 
approach called “turning off the tap” (34). Methods to halting transmission include 
improved case detection through active case finding and ensuring timely and adequate 
treatment of existing TB cases (34). 
 
Active Case Finding 
In most settings, TB is identified through passive detection in which individuals 
with symptoms seek care from a health facility or other health provider and are 
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subsequently diagnosed with TB in a clinical setting (35). This system puts the onus on 
the patient, and frequently leads to delays in diagnosis (36) or cases going undetected; 
globally it is estimated that 30% of cases are never diagnosed and notified to public 
health authorities (1). Not only does this meant the patient does not get the care they 
need (37), but because most transmission occurs prior to initiation of treatment (38), 
delays in diagnosis contribute to increased disease spread (39). 
Active case finding is an intervention that aims to detect and diagnose individuals 
with TB by actively seeking them out rather than waiting for them to seek care on their 
own (35). Active case finding can detect cases earlier in their disease course, so they 
may be less infectious and have had less opportunity for further transmission (40,41). 
Although resource intensive, active case finding can greatly increase the number of TB 
cases being diagnosed (42) and can be cost-effective (43). In order to be effective, it is 
critical that active case finding interventions take the local epidemiology into account 
(35,44). Active case finding approaches can be targeted to high-risk groups or 
population-based (45). 
Targeted active case can efficiently identify cases in known high-risk populations, 
such as people living with HIV (46), household contacts of TB cases (47), health care 
workers (48), and people living in prisons (49). For example, active case finding among 
people seeking care at HIV clinics has found TB prevalence of 8%, far higher than 
population-based testing (50). Recent contacts of TB cases are also at increased risk 
for TB (51). The WHO recommends household contact investigations due to their high 
yield (52,53), although in high-burden settings the majority of transmission occurs 
outside of the household so the effect on transmission may be limited (54). Institutional 
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transmission of TB is common in settings like prisons (55) and health care settings (56), 
making them ideal targets for case finding and halting transmission.  
Community or population-based active case finding tends to be lower yield 
compared to targeted interventions (50) but can reach people who do not fall into known 
high-risk categories and would otherwise be missed (57). While there is evidence that 
mass screening activities can lead to sustained reductions in TB incidence (34,58), the 
implementation of broad community-based case finding interventions has had mixed 
results (59–63). Challenges in implementation include access to the target population, 
choice of screening and diagnostic tests, and linkages to the health care system (57). 
For example, the ZAMSTAR trial conducted in Zambia and South Africa found no effect 
of its enhanced case finding intervention, but only reached 6% of the population in its 
door to door testing efforts. Lack of sensitive diagnostics may also limit the yield of 
active case finding among people with mild or asymptomatic disease (62). Active case 
finding in Brazil led to increased case detection but no improvement in treatment 
initiation or outcomes (60); other studies have shown that patients identified by active 
case finding are less likely to complete treatment than those detected by passive case 




Treatment for uncomplicated pulmonary TB currently requires six months of 
combination antibiotic therapy; the treatment course can be longer for those with 
extrapulmonary TB or drug resistance (66). Treatment can quickly reduce the 
 
 7 
infectiousness of a TB patient but if an adequate course of treatment is not completed 
the patient is at increased risk for treatment failure or relapse. Therefore, treatment is 
critical not just for the patient’s well-being but also to prevent ongoing transmission; 
early analyses suggested that treating infectious TB cases would be the most effective 
and cost-effective way to reduce TB transmission and mortality (67). 
However, only 85% of diagnosed TB cases completed treatment in 2017 (1). 
Using a patient cascade approach, it is estimated that less than 50% of all TB cases 
complete treatment due to health system losses (37). Barriers to treatment adherence 
include health system limitations as well as individual patient knowledge, perceptions, 
and stigma (68). In individual patients, risk factors for poor treatment outcomes include 
HIV co-infection, older age, and alcoholism (69). 
The primary strategy to improve treatment outcomes globally has been 
implementation of directly observed therapy (DOT), in which a healthcare provider or 
treatment supporter observes the patient taking their treatment (70). DOT, an important 
component of the WHO’s TB control DOTS strategy (71), has not been shown to be 
consistently effective compared to self-administered therapy (72); improvements in 
treatment adherence and outcomes are dependent on successful implementation of 
DOT (73). Other interventions to improve treatment adherence and completion include 
material incentives and enablers (74), patient counselling and education (75), and 
appointment reminder systems (76). These interventions have shown improvement in 
treatment outcomes in some settings but overall results in improving treatment 




End TB strategy and progress 
In 2015, the WHO launched the End TB strategy, a follow-up to previous global 
TB control strategies that focuses on ending the TB epidemic (78). The strategy is 
founded on three pillars: 1. Integrated, patient-centered TB care and prevention; 2. Bold 
policies and supportive systems; and 3. Intensified research and innovation (79). The 
End TB strategy set ambitious targets of reducing the number of TB deaths by 95% and 
the TB incidence rate by 90% by 2035 (compared to 2015). More recently, there has 
been increased political support for the End TB strategy, including the first ever high-
level United Nations (UN) meeting on TB held in September 2018. In this meeting, all 
UN member states reaffirmed their commitment to the End TB Strategy (1). Among 
other goals, they promised to find and treat 40 million TB cases by 2020; however, 
participants felt that the meeting fell short and were skeptical of the actual commitment 
to these goals (80). Others have expressed the need to improve access to prevention 
and treatment in order to reach the End TB goals and that more action is needed (81) 
Indeed, we are not on target to achieve the End TB goals. The annual reduction 
in incidence rate over the past five years has been less than 2%, far below that required 
to reduce TB incidence by 90% by 2035 (1). While interventions including active case 
finding and treatment of active TB cases have been shown to be effective, the broad 
application of these interventions has not had the population level impact that early 
models had suggested (82). A large “delivery gap” persists for TB and other health care 
issues in developing countries such that the interventions known to work are not 
reaching the people that need it most (83). This is in part due to a broad “one-size-fits-
all” approach to implementation of TB control interventions that fails to account for local 
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needs and contexts (84). This approach does not work in the reality that there is 
substantial heterogeneity of TB; even in areas of high burden the relative rarity of TB 
makes population-based interventions challenging (85). Therefore, in order to prioritize 
the efficiency of interventions, there is increasing interest in intensive and tailored small-
scale interventions that can have a large impact (86). The most successful and effective 
interventions match implementation to the local context of the epidemic (87,88). This 
research aims to use in-depth understanding of the local context of TB in urban Uganda 
to identify approaches for improving the efficiency of TB control interventions in this 
setting. 
 
Study location and context 
This research was conducted in Uganda, a WHO high-priority country (1). 
Uganda has an estimated TB prevalence of 253 per 100,000 population and 24% of 
diagnosed TB cases in Uganda are co-infected with HIV (89). There is substantial 
heterogeneity in the geographic distribution of both TB and HIV in Uganda, although 
they are closely correlated (90) and the prevalence of both diseases is higher in urban 
areas compared to rural areas (89,91). While there have been few in-depth studies of 
the local burden of TB, one study in a region of Kampala (the capital city) estimated a 
TB incidence more than three times higher than that estimated by the prevalence 
survey (92), suggesting the burden of TB in urban settings may be underestimated. In 
additional to traditional risk factors for TB, including HIV, smoking and alcohol use, and 
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poverty and overcrowding (93), fishing communities are a key population for TB in 
Uganda due to their living conditions and limited access to health care (94).  
The Uganda National TB and Leprosy Program (NTLP) oversees the provision of 
TB diagnosis and treatment services (95). These services are provided for free at public 
health facilities although patients often initially seek care in the private sector, which can 
lead to delays in diagnosis (96). Case detection and treatment completion remain 
challenges in Uganda. The NTLP primarily relies on passive diagnosis of TB cases 
which limits their ability to detect TB; only 39% of symptomatic TB patients have ever 
sought care for their symptoms, and 46% of TB cases go completely undetected (89). 
Although the national guidelines recommend that community-based DOT be provided 
and managed by a designated subcounty health worker, this is not widely enforced or 
monitored. Qualitative research suggests that facilitators of treatment success include a 
patient-centered approach to care and the use of village health teams; barriers to 
treatment success include lack of trained staff, funding shortages, and poor 
implementation of directly observed therapy (97). 
This research was conducted as part of the STOMP-TB study in three parishes in 
central Kampala, Uganda. This is a densely populated area (approximately 50,000 
people in less than 2.5 km2), including some slums, that had an estimated prevalence of 
more than 300 TB cases per 100,000 population prior to the initiation of this study. 
Given the known geographic heterogeneity of TB burden in this area, this research aims 
to use the spatiotemporal epidemiology of TB in this population in urban Uganda to 




Spatial Epidemiology and TB control 
The distribution of TB burden is not random or homogenous; spatial 
heterogeneity is demonstrated by varying national (1) and sub-national TB rates (98). In 
many countries, including Uganda, urban areas have higher burden of TB compared to 
rural ones, due to increased risk of exposure, infection, and disease associated with 
urban residence (99,100). Even within high-burden urban settings, there is often 
clustering of TB (100,101), particularly in the most densely populated (21,102) or 
extremely poor areas (21,103,104). Spatial clusters are often composed of individuals 
with similar risk factors, such as migrants (105,106), those with lower income or 
socioeconomic status (104,107–110), and people who use illicit drugs (108). While 
some of this clustering may be due to local transmission (107,108,111), clustering can 
also be driven these shared risk factors in the population (18). In programmatic settings, 
the molecular data required to identify local transmission is usually unavailable; 
therefore, interventions based on spatial data must use routine data to identify and 
prioritize areas for intervention. Spatially targeted interventions in high-burden urban 
settings can increase case notifications and diagnose cases earlier in their disease 
course, thereby reducing transmission (112,113). These geographically targeted 
interventions can also have a population-level effect on TB burden while focusing 
limited resources on the population that needs them the most (114). In aim 1, I 
considered the potential impacts of geographically targeted active case finding based 
on routinely collected TB notification rates, using a subsequent active case finding 
activity to assess whether TB notifications can predict the locations of undiagnosed TB 
in the community. 
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While the majority of geographically-prioritized interventions focus on TB burden 
based on location of residence, there is substantial evidence that in high-burden 
settings, most transmission is occurring outside of the household and may not be 
attributable to close contacts (54,115–119). Therefore, it is important to consider places 
outside of the immediate vicinity of the household where individuals spend time as 
potential locations for TB transmission (120). One approach to this is the assessment of 
geographic mobility, a special application of spatial epidemiology which considers not 
only locations but also movement patterns including distance and duration of travel 
(121). Geographic mobility may increase an individual’s exposure to TB by influencing 
the frequency or duration of contact with TB cases (116,122). For example, 
transmission of TB has been documented during travel (123–125) including on public 
transportation (126). In aim 2, I investigated patterns of geographic mobility among 
people seeking care for TB symptoms; I also assessed the relationship between 
mobility and both TB disease as well as care seeking behavior.  
In addition to potential risk for transmission or disease, location may affect TB 
epidemiology if it represents barriers to quality health care (127). People living in areas 
with high poverty rates, often correlated with TB burden, frequently experience 
limitations in their access to healthcare (102). For example, individuals who face a 
difficult journey between home and health facility, whether due to physical distance, 
travel time, or transport cost and availability, may face barriers to TB diagnosis and 
treatment (102,128). This may also be reflected in the choice of facility; the total cost to 
the patient may actually be lower if care is sought at a nearby private facility compared 
to a public facility that provides TB diagnosis and treatment for free but is further away 
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(83,96). There is evidence that geographic barriers may play a role in delays and loss to 
follow-up during the TB diagnostic process (129–131); in aim 3, I took that research a 
step further and investigated whether geographic barriers play a role in TB treatment 
outcomes.  
The spatiotemporal epidemiology of TB is increasingly of both programmatic and 
research interest as spatial methods become more readily available. Primarily, spatial 
scan and autocorrelation techniques are used to identify areas at high risk for TB; these 
analyses are often limited by the use of TB notification data, which may not represent 
the true underlying burden of TB in the population (98,132–135). In aim 1, I built on this 
existing research by using community-based active case finding as an empiric measure 
of the TB in the population, thereby allowing assessment of the impact of a 
geographically targeted active case finding intervention in this setting. Additionally, while 
spatial assessments of TB risk in high-burden settings increasingly consider locations 
outside of the home as potential transmission locations, often these investigations are 
specific to the study setting and not broadly generalizable (136). In aim 2, I considered 
geographic mobility as an individual behavior characteristic, not tied to specific locations 
but representing movement that may affect an individual’s risk for TB or care seeking 
behavior. The development of a definition of this mobility may be more widely applicable 
to identifying high-risk populations other high-burden settings that could be targeted for 
early case finding interventions. Finally, identifying populations for case finding 
interventions will have limited effect on the TB epidemic if those cases are not enrolled 
in care and cured; in aim 3, I considered the effect of location as a barrier to completing 
TB treatment.  
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At the local level, understanding these patterns can help inform geographically 
focused TB control interventions that efficiently target resources to the most high-need 
populations and reduce TB burden in these settings. From a research perspective, the 
development of methods to identify these high-risk populations that can be applied to 
other similar settings is critical. This research presents a combination of detailed 
understanding of the local context with methods that may be used in other high-burden 
settings to identify populations for active case finding and treatment adherence 
interventions, with the goal of reducing transmission and “turning off the tap” on TB 
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Chapter 2: Using spatial heterogeneity of facility-based TB notification rates to 






Background: Routine tuberculosis (TB) notifications are geographically heterogeneous, 
but their utility in predicting the location of undiagnosed TB cases is unclear.  
Methods: We used routinely collected data to identify geographic areas with high TB 
notification rates and evaluated the extent to which these areas correlated with the 
location of undiagnosed cases during a subsequent community-wide active case finding 
intervention in Kampala, Uganda. We first enrolled all adults who lived within 35 
contiguous zones and were diagnosed through routine care at four local TB Diagnosis 
and Treatment Units. We calculated average monthly TB notification rates in each zone 
and defined geographic areas of “high risk” as zones that constituted the 20% of the 
population with highest notification rates. We compared the observed proportion of TB 
notifications among residents of these “high-risk” zones to the expected proportion 
using simulated estimates based on population size and random variation alone. We 
then evaluated the extent to which these “high-risk” zones identified areas with high 
burdens of undiagnosed TB during a subsequent community-based active case finding 
campaign.  
Results: We enrolled 45 adults diagnosed with TB through routine practices and who 
lived within the study area (estimated population of 49,527). Eighteen zones reported no 
TB cases in the 9-month period; among the remaining zones, monthly TB notification 
rates ranged from 3.9 to 39.4 per 100,000 population. The five zones with the highest 
notification rates constituted 62% (95%CI 47-75%) of TB cases and 22% of the 
population – significantly higher than would be expected if population size and random 
chance were the only determinants of zone-to-zone variation (48%, 95% simulation 
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interval 40-59%). These five “high-risk” zones accounted for 42% (95%CI 34-51%) of 
the 128 cases detected during the subsequent community-based case finding 
intervention, which was significantly higher than the 22% expected by chance (p<0.001) 
but lower than the 62% of cases notified from those zones during the pre-intervention 
period (p=0.02). 
Conclusions: There is substantial heterogeneity in routine TB notification rates at the 
zone level. Using facility-based TB notification rates to prioritize high-yield areas for 






More than 10 million people were diagnosed with tuberculosis (TB) in 2018. This 
burden is not distributed equally; the majority of TB cases are found in 30 countries 
designated as high burden by the World Health Organization (1). Even within high-
burden countries, TB is geographically heterogeneous, often concentrated in densely-
populated, low-income areas (2). This small-scale geographic heterogeneity, as seen 
among city neighborhoods, may reflect local transmission (3–5) and is often associated 
with neighborhood characteristics such as crowding or poverty (6,7). Models have 
suggested that interventions targeted at hotspots could have a large impact on overall 
incidence (8,9). However, in order to be actionable, hotspots would need to be 
identifiable based on routine data and reasonably stable over the time between hotspot 
identification and subsequent intervention. Understanding whether these criteria are met 
could inform local-level prioritization of interventions, as is critical for TB control at the 
global level (10). 
In most high-burden settings, routine TB diagnosis depends on symptomatic 
presentation by patients, which places the burden on the patient to recognize their 
symptoms as warranting medical attention and to subsequently seek care. Such 
symptom-driven diagnosis often fails to detect TB in people with milder symptoms, 
groups with limited access to care, or areas with limited clinical resources (11,12). A 
recent prevalence survey in Uganda estimated that these current practices fail to detect 
46% of TB cases (13). Active case finding, in which resources are leveraged at the 
community level to identify TB cases and link them to care, is therefore essential to 
detect undiagnosed TB in communities (14,15) and further reduce the burden of TB 
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(16). However, active case finding is resource intensive, and studies of broad 
community-wide active case finding have had mixed results (17–21). Targeted 
approaches to active case-finding, by focusing on people at higher-than-average risk for 
TB such as recent contacts of TB cases or persons living with HIV, are therefore 
important (22,23). Geographic targeting is an approach to TB case finding that may be 
feasible but has not been widely implemented, largely because of uncertainty regarding 
whether cases identified through routine systems can predict the locations of 
undiagnosed prevalent cases in the community.  
A better understanding of local geographic heterogeneity in routinely identified 
TB cases and the correlation of that heterogeneity with the location of undiagnosed 
prevalent cases may therefore be useful in directing active case finding interventions to 
high-risk areas. We used routinely collected TB diagnosis data to identify small-scale 
geographic areas with high notification rates in Kampala, Uganda. We then evaluated 
the degree to which these areas contain a higher proportion of undiagnosed prevalent 
TB, using a subsequent community-wide active case finding intervention.  
 
Methods 
Study Overview and Population 
This was a community-based study conducted in Kisugu, Wabigalo, and Bukasa 
parishes in Kampala, Uganda (an area of 2.2 km2 with an estimated population of 
49,527) from May 2018 through December 2019. The study site consists of 37 
contiguous zones; zones are the smallest standard administrative area unit used by the 
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Uganda Bureau of Statistics, with a median size of 0.05km2 within the study area. Prior 
to initiation of the study, a door-to-door census was conducted by the study team to 
estimate the population of each zone. Zones with a population of less than 500 were 
merged with neighboring zones with similar characteristics such that all areas for 
analysis had a population of at least 500 in order to ensure that each unit of analysis 
would contain at least two TB cases assuming spatial homogeneity and an anticipated 
TB prevalence of 400 cases per 100,000 population. Two zones for which the census 
could not be completed were excluded, resulting in 33 areas for analysis. 
 
Case definition 
A TB case was defined as any individual with a positive sputum smear or 
GeneXpert result, sputum culture positive for Mycobacterium tuberculosis, or 
documented initiation of TB treatment based on clinical judgment of pulmonary 
tuberculosis. The GeneXpert (“Xpert”) system (Cepheid, Inc., Sunnyvale, CA, USA) was 
the primary test used for the study. Sputum samples were tested using Xpert MTB/RIF 
cartridges at the beginning of the study; the Xpert Ultra cartridge was implemented in 
February 2019. Sputum smears were used based on clinician request and were rare. 
Sputum culture was generally only performed for research purposes after TB diagnosis 
by other means; thus, TB diagnosis based only on culture was very uncommon. In this 
analysis, we included only individuals who were age 15 years or older and residing 
within the study area; zone of residence was self-reported and verified using landmarks 
and Google Maps. We conducted a sensitivity analysis using a case definition that only 





Case Detection and Enrollment 
The study prospectively enrolled TB patients in two phases: a facility-based 
phase (May 2018-January 2019) and a community-based phase (February-December 
2019). In the facility-based phase, we enrolled all consenting adult TB cases who lived 
in the study area and were passively identified through routine TB diagnostic services at 
four outpatient TB Diagnosis and Treatment Units located within the study area. 
Clinicians at the facilities were responsible for making TB diagnoses based on clinical 
judgment and the results of any laboratory tests (for example, sputum smears); 
diagnosed cases were then referred for study enrollment.  
In the community-based phase, we attempted to identify all prevalent TB cases in 
the community through a combination of passive and active case finding activities. 
Passive case detection continued at the four health facilities as described above. We 
also conducted door-to-door sputum collection and testing throughout the study area; 
this included participants who were at a residence other than their own at the time of 
testing as long as their residence was within the study area. Ten venue-based 
screening events were held at churches, markets, and other community locations in 
order to reach those who were not available during door-to-door testing. Contact 
investigation was also completed for all identified cases. If residents could be contacted 
but were not available at the time of screening, follow-up home appointments were 
scheduled. The goal of the community-based phase was to obtain a sputum specimen 





Facility-based TB Rates 
Average monthly TB notification rates (per 100,000 population) for the facility-
based study phase were calculated by zone as: (number of TB cases residing in that 
zone)/(estimated population of the zone * facility-based phase duration, in months). We 
then ranked zones according to their average monthly TB notification rates and defined 
a “high-risk” group of zones by starting with the zone reporting the highest TB 
notification rate and including additional zones with the next-highest rates until the 
“high-risk” category accounted for at least 20% of the population. The 20% cutoff was 
an a priori threshold corresponding to the likely size of any targeted case-finding 
intervention that could be undertaken in the study area; sensitivity analyses were 
conducted using cutoffs of 10%, 15%, 25%, and 30% of the population. We calculated 
the proportion of facility-based phase TB cases who resided within the high-risk group 
of zones and a corresponding 95% confidence interval, assuming a binomial 
distribution. We compared demographic, clinical, and behavioral risk factors among 
cases residing in the high-risk vs. low-risk zones using Fisher’s exact tests for 





Estimation of expected spatial distribution of TB cases 
To estimate the number of facility-based TB cases that would be expected to 
occur in the high-risk zones based on chance alone, we conducted 1,000 stochastic 
simulations in which we assumed that the only driver of spatial heterogeneity in TB 
notification rates was random variation. For each simulation, we randomly assigned to 
each zone a number of TB notifications based on population size by drawing a value 
from a Poisson distribution with mean of (total number of TB cases in study area during 
facility-based phase * proportion of total population residing in that zone). As with the 
observed data above, we then sorted the zones by the simulated TB rate (simulated 
number TB notifications per 100,000 population per month) and identified the “high-risk” 
zones as those representing the 20% of the simulated study population with the highest 
simulated TB notification rates. These simulated high-risk zones therefore occurred 
randomly throughout the study area, varying from one simulation to the next, and did 
not correlate with the actual observed high-risk zones. For each simulation, we then 
calculated the cumulative proportion of TB notifications occurring among residents of 
these simulated high-risk zones – thereby providing an estimate of the proportion of TB 
notifications that would be expected to occur in high-risk zones if the only determinant of 
“high-risk” were random variation in the spatial distribution of TB notifications. We used 
the 2.5 and 97.5 percentiles of our simulations to define the corresponding 95% 




Stability of facility-based notifications over time 
We compared cases diagnosed passively at the health facilities during the 
facility-based and community-based phases to determine whether there were changes 
in the spatial distribution of facility-diagnosed cases over time. We calculated the 
proportion of passively-diagnosed community-phase cases with 95% confidence 
intervals using a binomial distribution and compared this proportion to the proportion 
from the facility-based phase using a chi-square test. 
 
Prediction of community-based prevalence using facility-based notifications  
We used all cases from the community-based phase to represent the true 
underlying distribution of prevalent TB. For each zone, we used data from the facility-
based phase to calculate an expected number of TB cases that would be found during 
the community-based phase, by multiplying the proportion of facility-based phase TB 
cases residing in each zone by the total number of TB cases found in the community 
phase. The expected number of community-based phase TB cases in each zone was 
compared to the observed number of TB cases found using a chi-squared test. The 
observed proportion of community-based phase TB cases residing within the high-risk 
zones (as defined during the facility-based phase) was calculated, with corresponding 
95% confidence intervals using a binomial distribution, and compared to the proportion 
from the facility-based phase using a chi-square test. We also conducted a sensitivity 
analysis using only community-phase cases that were diagnosed via community-based 
active case finding (excluding those diagnosed at the health facilities during the 
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community-based phase) to represent the cases that would be expected to be found via 
a case finding intervention informed by notification data from the facility-based phase.  
 
Results 
Facility-based TB notifications 
During the facility-based phase, 45 cases were notified at the four participating 
facilities through routine care. These cases resided in 15 different zones in the study 
area; among those zones, the average monthly TB notification rate ranged from 3.9 to 
39.4 TB cases per 100,000 population per month (Figure 1, panel A). One zone in 
Bukasa parish accounted for 11 of the 45 (24%) TB cases diagnosed during this phase 
(Table 1). The five zones with the highest TB notification rates were classified as “high-
risk.” These zones accounted for 22% of the population but 62% (95%CI 47-75%) of 
routinely diagnosed TB cases during the facility-based phase.  
 
Compared to facility-based cases from other zones, facility-based TB cases from 
the high-risk zones were more likely to be female (11/28 [39%] vs. 3/17 [18%]), self-
employed (10/28 [36%] vs. 2/12 [12%]), lower income (median monthly income 340,000 
Ugandan Shillings [UGX] vs. 600,000 UGX), and HIV positive (11/38 [39%] vs 2/12 
[12%]) (Table 3). They were less likely to be able to read and write without difficulty 
(13/28 [46%] vs. 5/17 [71%]) or to have known any other TB cases (7/28 [25%] vs. 8/17 




Expected spatial distribution of TB cases 
Under the assumption that the only variation in spatial distribution of TB cases 
was random chance, we estimated that 47% (95% simulation interval 39-58%) of TB 
cases would come from “high-risk” zones accounting for the same fraction of the 
population (22%), a lower percentage than the observed 62%. The results of sensitivity 
analyses using cutoffs of 10%, 15%, 25%, and 30% of the population are shown in 
Table 2. 
 
Stability of facility-based notifications over time 
Among passively-diagnosed (health facility) cases during the community-based 
phase, 32% (95% CI 18-50%) were residents of the high-risk zones as defined by the 
facility-based phase, significantly lower than would be expected if facility-based 
diagnoses were constant over time (p=0.009).  
 
Prediction of community-based prevalence using facility-based notifications 
During the community-based phase, 128 people were diagnosed with TB; these 
individuals resided in 27 different zones. Among these 27 zones, the average monthly 
TB notification rate ranged from 8.3 to 120.0 TB cases per 100,000 population (Figure 
1, panel B). The five zones classified as “high-risk” based on the facility-based phase 
(22% of the study population) accounted for 42% (95% CI 34-51%) of the TB cases in 
the community-based phase,  which was significantly higher than the 22% expected by 
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chance (p<0.001) but lower than the 62% of cases notified from those zones during the 
pre-intervention period (p=0.02).  
The location of the five high risk zones is shown in Figure 2. Three of the five 
form a contiguous area in Bukasa parish. If this area were to be defined as a single 
intervention zone, this area would account for 18% of the total population, 51% (95% CI 
36-66%) of the routinely diagnosed TB cases in the facility-based phase and 40% (95% 
CI  32-49%) of TB cases diagnosed in the community-based phase.  
 
Sensitivity analyses of case definition 
When considering only microbiologically confirmed cases (32/45 facility-based 
phase cases and 125/126 community-based phase cases), six zones accounting for 
21% of the population had 59% (95% CI 41-75%) of facility-based phase TB cases; 
three of these zones were the same as in the primary analysis. We estimated that 53% 
(95% simulation interval 43-66%) of TB cases would come from “high-risk” zones 
accounting for the same fraction of the population (21%), based on random variation 
and population size alone. In the community-based phase, 40% (95%CI 32-49%) of 
cases came from these 6 “high-risk” zones. 
 
Sensitivity analyses for active case finding 
In the community-based phase, 34 (27%) cases were diagnosed at one of the 
four health facilities via routine services. In our sensitivity analysis excluding these 
cases, the five high-risk zones from the facility-based phase in the primary analysis 
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accounted for 46% (95% CI 36-56%) of cases detected via active case finding activities 
(door to door testing, venue based screening events, and contact investigation). 
Discussion 
This study in Kampala, Uganda, found evidence of spatial heterogeneity of TB 
burden within an urban, densely-populated area using routinely collected TB notification 
data, with 22% of the population accounting for 62% of cumulative TB notifications. 
Data from a subsequent community-based active case finding activity demonstrated 
that routine TB notifications can be used to identify geographic areas with a high 
underlying burden of TB; for example, the same 22% of the population accounted for 
42% of the cases diagnosed during a subsequent case-finding intervention. Geographic 
targeting could therefore double the yield of active case finding interventions in this 
setting.  
Interventions targeted at small geographical scales have not been widely 
implemented for TB, but locally focused prevention and case finding interventions have 
been shown to reduce the burden and transmission of HIV (24), malaria (25), and other 
neglected tropical diseases (26). Based on our results, targeting 22% of the population 
in an urban high-burden area could identify 42% of TB cases in that population. While 
we chose a cutoff of 20% of the population as a reasonable size to screen, targeted 
interventions even in this subpopulation would be resource intensive and logistically 
challenging. To further improve the feasibility of geographically targeted interventions, it 
may make sense to focus on a single contiguous area. In this study, three of the five 
“high-risk” zones (Figure 2) were geographically contiguous, suggesting a possible 
intervention area. However, this analysis does not account for the increased cost and 
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human resources required to conduct comprehensive interventions in targeted (often 
underserved) areas with populations that may be highly mobile; in other studies, the 
per-case-detected costs of active case finding in high TB burden areas have been 
shown to be high (27,28). Intervention-specific cost and epidemiological data would be 
needed to estimate the impact and cost-effectiveness of any particular intervention in 
this setting.  
Spatial analyses of TB have been primarily limited to using TB notification data 
(29) and are therefore unable to assess whether high notification rates are due to high 
prevalence of TB in the community or improved access to TB diagnosis (30). Numerous 
studies in high-burden countries have shown that TB notifications are limited by 
underdiagnosis and under-reporting (14,15,31–35), but it is not clear whether the 
location of residence of the reported TB cases represents that of the missed cases. Our 
analysis suggests that, in this setting, facility-based TB notifications can reasonably 
predict the location of prevalent TB cases, suggesting that geographically targeted 
active case finding using routine notifications to define the target zones could be 
effective in this area. This is a strength of small-scale geographic analysis in our 2.2 km2 
study area, as access to health care may be relatively homogeneous. In settings where 
low notification rates may represent poor access to services, notifications are likely to 
be less useful in targeting areas for further TB-related interventions.  
The population denominators on which our estimates of zone-level TB rates are 
based used census estimates collected by our research team; official population 
estimates are not available from the Uganda Bureau of Statistics at this scale, which 
may limit the ability of other regions to apply these methods. While our population 
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estimates may be imprecise, they are the first to be estimated at the zone level in this 
area, and there is no a priori reason to expect that any biases in population estimates 
would be differential from one zone to the next. Our community-based phase was 
conducted shortly after the facility-based phase, reflecting how a geographically 
targeted case finding intervention may be implemented, but the lack of stability in 
geographic distribution of facility-based notifications over time may make it difficult to 
accurately predict the location of undiagnosed cases. Our sample size was small, 
leading to imprecise estimates – but such sample sizes are likely to be representative of 
real-world interventions that might seek to target TB activities on small geographic 
scales over realistic time frames. Finally, given the urban, densely population nature of 
our study setting, these results may not be generalizable to rural settings or different 
epidemiological contexts; however, these methods could be applied in different settings 
using routinely available data. 
In conclusion, we show that there is substantial geographic heterogeneity in the 
residence of routinely diagnosed TB patients. We identified high risk zones using data 
routinely collected at health facilities and show that it may be possible to detect more 
than 40% of undiagnosed TB cases in the community by screening approximately 20% 
of the population. Comparison of the spatial distribution of passively diagnosed cases 
with those identified via community-wide active case finding suggests that 
geographically prioritized case finding may be an efficient way to detect prevalent TB in 
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Tables and Figures 
Figure 2.1. Average Monthly TB Notifications, by zone (per 100,000 population)  
This figure shows the average monthly TB notification rate per 100,000 population by 
zone as estimated in (A) the facility-based phase, where TB cases were passively 
diagnosed via routine standard of care practices from May 2018 to January 2019 and 
(B) the community-based phase, where additional active case finding activities were 
implemented throughout the study area from February to December 2019. Numbers 
indicate each zone’s rank (from 1-15) based on average monthly TB notification rates 
during the facility-based phase – with no numbers assigned to zones in which no TB 
cases were diagnosed during that phase. High-risk zones (outlined in bold) were 
selected using notifications from the facility-based phase by starting with the zone 
reporting the highest TB notification rate and including additional zones with the next-
highest rates until the “high-risk” category accounted for at least 20% of the population, 
resulting in five zones. Two zones did not have population data available to inform 







Table 2.1. Observed TB Notifications by Zone and Phase of Case Detection in Urban Uganda 



























Bukasa Namuwongo A 11 3299 39.4 1 0.07 0.24 31 120.0 0.25 
Kisugu South B 3 906 39.1 2 0.08 0.31 1 14.1 0.25 
Bukasa Yoka 7 2793 29.6 3 0.14 0.47 13 59.4 0.36 
Wabigalo Klezia 2 950 24.9 4 0.16 0.51 1 13.4 0.37 
Bukasa Namuwongo B 5 2705 21.8 5 0.22 0.62 8 37.8 0.43 
Kisugu Kasanvu 4 2471 19.1 6 0.26 0.71 10 51.7 0.50 
Kisugu South AC 1 809 14.6 7 0.28 0.73 4 63.1 0.53 
Wabigalo Project 2 1739 13.6 8 0.32 0.78 2 14.7 0.55 
Kisugu Upper Zone 2 1742 13.6 9 0.35 0.82 4 29.3 0.58 
Wabigalo Central 2 1898 12.4 10 0.39 0.87 11 74.0 0.66 
Wabigalo Kitooro 1 1166 10.1 11 0.41 0.89 0 0.0 0.66 
Kisugu Go Down 1 1202 9.8 12 0.44 0.91 7 74.3 0.72 
Wabigalo Industrial 1 1302 9.1 13 0.46 0.93 2 19.6 0.73 
Kisugu Lakeside 2 2701 8.7 14 0.52 0.98 2 9.5 0.75 
Kisugu Mugalasi 1 3062 3.9 15 0.58 1 2 8.3 0.77 
18 zones reporting 0 cases 
in the facility-based phase 


































percentage of TB 
cases in the “high-
risk” area (95% CI) 
5% 7% 1 24% (14-39%) 19% (44-26%) 
10% 14% 3 47% (32-62%) 35% (28-44%) 
15% 16% 4 51% (36-66%) 38% (31-48%) 
20% 22% 5 62% (47-75%) 47% (39-58%) 
25% 27% 6 71% (56-83%) 55% (46-66%) 
1 The actual percentage is higher than the cutoff percentage because the actual “high-
risk” area consists of intact zones, added sequentially to the “high-risk” area until the 
cutoff is surpassed. 
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Figure 2.2. Potential Implications of Geographic-Targeted Screening 
High-risk zones as defined by the facility-based phase TB notification rates are 
indicated in purple. Numbers indicate each zone’s rank (from 1-15) based on 
average monthly TB notification rates during the facility-based phase – with no 
numbers assigned to zones in which no TB cases were diagnosed during that 
phase. While targeted active case finding at each selected zone may not be 
feasible for logistical and political reasons, we highlight that the easternmost 
three of the five high-risk zones are contiguous and within Bukasa parish (parish 
boundaries are designated in bold). If this area were to be defined as a priority 
for case finding activities, it would represent 18% of the total population, 23/45 
(51%) of facility-based phase TB cases, and 52/128 (40%) of the community 
phase TB cases. Two zones did not have population available and were 
excluded from this analysis.                 
 
 
Three zones combined: 
18% of the total population 
51% of the facility TB cases  
40% of the community TB cases 
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Figure 2.3. Comparison of observed TB notifications in high-risk zones to 
expected cases due to chance  
Panel A orders the 35 zones the study area according to each zone’s facility-
based phase TB notification rate (also provided in Table 1); the red line shows 
the cumulative proportion of TB cases notified who reside in “high-risk” zones (y-
axis) according to the cumulative proportion of the population in the “high-risk” 
zone (x-axis). The shaded area corresponds to the 95% simulation interval (2.5th 
and 97.5th percentiles) from 1,000 simulations that assume the observed 
population size in each zone and observed total number of TB notifications, but 
assign TB cases to zones under the assumption that spatial heterogeneity of TB 
notifications in the area is driven only by population size and random chance. 
The vertical line at 22% of the cumulative population represents the cutoff for 
“high-risk” zones used in our primary analysis and shows that 62% of facility-
based cases resided in “high-risk” zones, significantly higher than the 
corresponding simulation interval of 40-59%. Panel B compares the same 
observed facility-based phase cases from Panel A (red line) with the cumulative 
proportion of TB cases identified through active case finding during the 
community-based validation phase (blue line), with the zones ordered according 
to TB notification rates during the facility-based phase. The vertical line in this 
panel shows that 42% of community-based phase cases resided in the “high-risk” 
zones (22% of the population) identified based on notifications during the facility-
based phase.  




     
  






Table 2.3. Demographic and clinical comparison between routinely 




High- Risk Zones 
(N=28) 




  N (%) N (%) 
Female 11 (39%) 3 (18%) 0.19 
Age at TB diagnosis     0.46 
15-24 years 4 (14%) 3 (18%)   
25-34 years 10 (36%) 8 (47%)   
35-44 years 11 (39%) 3 (18%)   
45-54 years 3 (11%) 3 (18%)   
Literacy     0.28 
Can read & write without difficulty 13 (46%) 12 (71%)   
Can read & write, but one or both are difficult 13 (46%) 5 (29%)   
Can neither read nor write 2 (7%) 0 (0%)   
Occupation     0.52 
Self-employed 10 (36%) 2 (12%)   
Student 1 (4%) 1 (6%)   
Salaried worker 7 (25%) 6 (35%)   
Occasional work (piece jobs) 4 (14%) 4 (24%)   
Unemployed but able to work 3 (11%) 3 (18%)   
Unemployed and unable to work 3 (11%) 1 (6%)   
Monthly income (Ug Shillings x1000), 
median (IQR) 340 (136) 600 (350, 750) 0.06 
Skipped 1+ Meals in the last month1 19 (68%)  7 (41%)  0.12 
Household Size, median (IQR) 2 (1, 3) 3 (1, 5) 0.35 
Duration of cough (weeks), median (IQR) 5 (3, 12) 8 (4, 20) 0.08 
HIV Positive 11 (39%) 2 (12%) 0.09 
Ever lived with a TB Case 6 (21%) 5 (29%) 0.37 
Ever known a TB Case 7 (25%) 8 (47%) 0.08 
1 Participant or other adults in their household reported skipping at least one meal or eating 








Chapter 3: Characterization of Geographic Mobility among patients at TB 






Background: International and internal migration are key risk factors for 
tuberculosis (TB). Geographic mobility, including small-scale travel for work, 
education, or personal reasons, may also play a role in TB but is poorly defined. 
We aimed to describe geographic mobility patterns among patients seeking TB 
diagnostic services in Kampala, Uganda and to assess the associations of this 
mobility with TB disease and access to care.  
Methods: This was a facility-based case control study conducted at four 
outpatient health facilities providing TB diagnostic and treatment services in 
Kampala, Uganda. We enrolled confirmed TB cases age ≥15 residing in the 
study catchment area; each case was matched with 2 controls. Participants self-
reported seven characteristics of geographic mobility which were used to conduct 
a latent class analysis (LCA) and create a definition of mobility. We assessed 
association of mobility and delays in diagnosis using non-parametric Wilcoxon 
rank-sum tests for cases and controls separately. We evaluated the association 
of mobility and TB case status using conditional logistic regression. 
Results: We enrolled 101 cases and 202 matched controls. Cases were more 
likely than controls to have lived in their neighborhood for more than a year 
(p=0.02); there was no difference between cases and controls in the remaining 
mobility characteristics. The LCA model with the best fit had 2 classes; the 
“mobile” class was largely driven by travel > 3 km from residence ≥9 times per 
month (84% vs. 2%) and spending ≥6 hours away from home when traveling >3 
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km from residence (78% vs 17%). Mobility was not associated with TB case 
status (adjusted odds ratio 0.85, 95% CI 0.44, 1.6), duration of symptoms (cases: 
p=0.73; controls p=0.6) or number of healthcare visits (cases: p=0.42; controls 
p=0.03) prior to the visit of enrollment. 
Conclusions: We provide the first description of mobility characteristics in a TB 
care seeking population and developed a definition of mobility based on 
frequency and duration of travel > 3 km from home. While this definition of 
mobility was not associated with TB case status or barriers to care, more 





Tuberculosis (TB) is a leading cause of morbidity and mortality globally, 
contributing to an estimated 10.0 million cases and 1.2 million deaths in 2018 
(1,2). Mobile and migratory individuals are a key population at risk for TB 
infection and disease (3). Mobile individuals may be more likely to acquire or 
transmit TB (4,5) and often experience barriers to TB diagnosis and treatment 
(6,7). While most research on TB and migration is focused on international 
migration (3), internal mobility such as rural-urban migration (8,9), labor migration 
(10), and nomadic populations (11–13) have also been shown to be at high risk 
for TB and to experience barriers to TB care. 
Many studies on mobility have focused on HIV in defined populations that 
are known to experience high mobility. For example, studies have shown truck 
drivers to be at high risk of acquiring (14–16) and transmitting HIV (17) and to 
have limited access to health care (18). Agricultural migrant workers have also 
been shown to be at increased risk for HIV (19,20). However, mobility may exist 
in less defined scenarios, such as due to marriage, work, or education (21), and 
there is no single definition of this geographic mobility. Studies of mobility and 
HIV have considered frequency (20,22–24) and duration of travel from home 
(22), number of nights spent away from home (20,22–25), circular or temporary 
migration (26), as well as distance traveled or internal borders crossed 
(21,22,24), but no studies have applied these definitions to TB.  
We aimed to develop a broader understanding of generalized mobility 
patterns. We described mobility patterns among patients seeking care at four TB 
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diagnostic and treatment units in Kampala, Uganda. We also assess the 
relationship between mobility and access to care and TB risk. Identifying mobility 
characteristics that affect health seeking behaviors or disease transmission is 
important for providing services in this hard to reach population. 
 
Methods 
Study population  
We prospectively enrolled patients presenting for TB testing at one public 
and three private outpatient TB Diagnosis and Treatment Units in Kampala 
between May 22, 2018, and January 31, 2019. Eligibility criteria included age ≥15 
years and residence within the study area, consisting of three parishes (Kisugu, 
Wabigalo, and part of Bukasa; estimated population: 49,527, total area 2.2 km2). 
For the time period between June 25, 2018, and January 1, 2019, we also 
enrolled participants from Kisugu Health Center (the public facility) regardless of 
their residence. TB cases were defined as patients diagnosed with pulmonary TB 
by the treating clinician, regardless of microbiological test result; however, most 
cases were confirmed with sputum Xpert MTB/RIF. For each case, two controls 
matched by facility and location of residence (within study area vs. outside study 
area, for the participants from Kisugu Health Center) were enrolled. Controls 
were randomly selected from eligible individuals who presented to the same 
treating facility and were tested for pulmonary TB but had a negative Xpert 
MTB/RIF result and were not empirically treated for TB. Data collection included 




Measurement of components of geographic mobility 
We defined a priori seven components of mobility and collected 
information through patient self-report. These measures and their categorization 
are shown in Table 3.1. As a sensitivity analysis for the continuous variables 
(frequency and duration of travel further than 3km from home), in addition to 
using the median to dichotomize the variable, we also considered the 25th and 
75th quartiles as cutoffs.  
 
Classification of mobility 
We used a latent class analysis (LCA) to inform our definition of mobility. 
The construct of mobility as a latent variable is shown in Figure 3.1. We 
conducted latent class analysis with a logit link using these seven variables as 
defined above using our entire study population. To determine the number of 
classes that provided the best model fit, we considered models with 1-4 classes 
and selected the model with the lowest Bayesian Information Criterion (BIC). We 
then characterized the classifications of mobility based on the LCA marginal 
means and assigned each participant to a mobility class. 
 
As described below, the results of the LCA were very similar to a 
dichotomous definition of geographic mobility. We compared a calculated 
definition of mobility (observed, rather than latent) to the classes predicted by the 




Mobility and Access to Care 
We defined two variables to indicate barriers to care. Symptom duration 
prior to current visit was calculated as the time from the self-reported start of the 
first symptom (cough, fever, night sweats, or weight loss) to the date of the 
patient’s interview. We also elicited the number of self-reported health care visits 
during this time. Both symptom duration and number of health care visits were 
compared for mobile vs. non-mobile patients (based on the definition of mobility 
above) in cases and controls separately using non-parametric Wilcoxon rank-
sum tests. 
 
Mobility and TB case status 
Using our calculated definition of mobility, we described the characteristics 
of mobile vs. non-mobile persons, stratified by TB case status, using chi-squared 
tests. We then assessed the association of mobility with TB case status (case vs. 
control) using conditional logistic regression, adjusting for possible confounders. 
Due to the large number of potential confounders, covariates with p-value<0.05 
in the bivariate analysis were included in the final model.  
 
Results 
Study population  
We enrolled a total of 303 participants (101 TB cases and 202 matched 
controls). Cases generally had similar mobility characteristics compared to 
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controls, although they were less likely to have lived in their current 
neighborhood for less than 1 year (p=0.02) (Table 3.1). Cases were less likely to 
be female (39% vs 60%, p<0.001) or to live in a household with 3 or more people 
(38% vs. 55%, p=0.006) and were more likely to report limitation in at least one of 
the 5 EQ-5D domains (physical mobility, self-care, usual activities, 
pain/discomfort, anxiety/depression) (75% vs. 57%, p=0.002) compared to 
controls. Cases were also more likely to have been to prison (46% vs 23%, 
p<0.001) and to have been treated for TB in the past (26% vs 10%, p<0.001).   
 
Classification of mobility 
We selected the model with two latent classes as the best fit based on BIC 
(Table 3.S1 and Figure 3.S1 in Supplement). One class was characterized as 
“mobile” based on higher marginal means for the following characteristics: travel 
more than 3 km from residence ≥9 times per month (84% vs. 2%), spending ≥6 
hours away from home when traveling more than 3 km from residence (78% vs 
17%), and traveling outside Kampala at least once in the last year (81% vs 68%) 
(Figure 3.2, Table 3.S3 in Supplement). People in this mobile class were more 
likely to have lived in the current neighborhood of residence at least one year 
(13% vs. 29%). These results did not change in sensitivity analyses that varied 
the cutoffs for dichotomizing frequency and durations of travel >3 km. Applying 
these classes to our patient population, we categorized 175 (57.8%) participants 




Calculation of Mobility 
Based on the results of the LCA, we considered a definition of geographic 
mobility as traveling further than 3 km from home at least 9 times per month or 
spending at least 6 hours away from home when traveling further than 3 km. 
Using this definition classified 94% (N=284/303) of patients in the same mobility 
category as predicted by the LCA. The remaining 19 patients were categorized 
as non-mobile in the LCA but mobile based on this calculation; however, the 
probability of being in the non-mobile class from the LCA was lower among these 
19 patients (63%, 95% CI 53-80%) compared to all patients categorized as non-
mobile (90%, 95% CI 53-99%). 
 
Characteristics associated with mobility 
Among both cases and controls, mobile patients were more likely to be 
men (cases: 76% vs. 38%, p<0.001; controls: 48% vs. 26%, p=0.002) and 
employed (cases: 87% vs. 51%, p<0.001; controls: 77% vs. 57%, p=0.011); 
mobile patients were also less likely to report limitations in any of the five EQ-5D 
domains (cases: 66% vs. 90%, p=0.007; controls: 53% vs. 66%, p=0.083) (Table 
3.3). Among controls only, mobile patients were more likely to have difficulty 
reading or writing (67% vs. 42%, p=0.004) and were less likely to have known 




Mobility and access to care 
While the median duration of symptoms among cases (8 weeks [IQR 4-
12]) was higher than among controls (3 weeks [IQR 2-8]), there was no 
significant difference between mobile and non-mobile patients among either 
cases or controls (Table 3.S5 in Supplement).  
The median number of symptom-related visits was 4 (IQR 2-7) among 
cases and 3 (2-6) among controls. There was no significant difference between 
mobile and non-mobile cases; among controls, the number of visits was slightly 
higher in non-mobile populations (p=0.03) (Table 3.S5 in Supplement). 
 
Mobility and TB Case Status 
Among TB cases, 61% (n=62) were classified as mobile compared to 65% 
(n=132) controls (p=0.50). Mobility was not associated with TB case status 
(adjusted odds ratio 0.85, 95% CI 0.44, 1.6). In multivariable analysis, previous 
treatment for TB (aOR 2.8, 95% CI 1.3, 5.9) or limitation in any of the EQ-5D 
domains (aOR 2.0, 95%CI 1.1, 3.8) were associated with TB case status. Female 
patients (aOR 0.40, 95% CI 0.20, 0.8) were less likely to have TB. 
 
Discussion 
Mobility may be a key factor in infectious disease epidemics, as it may be 
related to transmission of disease or represent a population that faces challenges 
in accessing health care. In this analysis of over 300 individuals presenting for 
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TB diagnosis in urban Uganda, we found that mobility was best defined by the 
frequency and number of trips further than 3 km from home residence. However, 
we did not find an association between this definition of mobility and delays in TB 
evaluation or risk of TB disease.  
 
There is no consistently applied definition of mobility, but our definition of 
mobility was similar to that used in other studies of mobility in sub-Saharan Africa 
(20,22–24). A strength of our definition is that it was determined using a data 
driven approach based on our latent class analysis. Some studies distinguish 
between internal migration and travel as components of mobility (21); we 
considered both in our LCA but ultimately only used travel in our final definition. 
Additionally, our use of a 3 km cutoff, designed to capture travel beyond the 
participants’ neighborhood, was unique in the definition of mobility. We did 
consider longer travel distance (outside of Kampala), which is similar to inter-
district travel used in other studies (21) but found that shorter distance better 
distinguished the classes of mobility. However, we did not collect information on 
nights spent away from the home, which is a common component of mobility in 
other studies (20,22–25).  
 
While we hypothesized that mobile populations would be at increased risk 
for TB disease (due to increased range of contacts) and may experience barriers 
to care due to an unstable lifestyle, we did not observe such associations in our 
analysis. The effect of mobility on disease outcomes and barriers to care is likely 
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driven by the cause and context of mobility, which we are unable to assess in this 
simplified analysis. There has been conflicting evidence as to whether mobile 
populations have more or less exposure to education campaigns and whether 
they experience greater or fewer barriers to care (27,28). Our analysis suggests 
that mobile individuals are more likely to be employed and less likely to report 
limitations on any of the EQ-5D domains, which may suggest that they are 
healthier and of higher socioeconomic status (supported by the result that mobile 
individuals were more likely to be in the highest quartile of income among both 
cases and controls) than non-mobile individuals, putting them at lower risk for 
disease and experiencing barriers to care. Other mobile populations have been 
shown to be at increased risk for TB, and interventions targeting these 
populations have been successful in providing TB diagnostic and treatment 
services for truck drivers in India (29) and nomadic populations in Nigeria (13) 
and Iran (12). Migrant-centered care, including mobile clinics, expanding service 
hours, flexible treatment options, or health passports may be appropriate 
services for this population (3).  
 
Limitations of our study primarily center on the measurement of mobility. 
Mobility questions were assessed via self-report in patient interviews and may be 
subject to misclassification or bias. Additionally, we asked a set of questions that 
may not capture every component of mobility; for example, we did not elicit 
number of nights spent away from home and reasons for travel. GPS trackers 
have been used in other studies and can capture continuous information that can 
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be used to calculate additional indicators (30,31) and may provide more reliable 
information (30,32). However, our approach using an LCA contributes to the 
development of a mobility definition that may be applied to other populations. Our 
interviews were conducted only at the time of seeking TB diagnostic services; 
participants, particularly those who were diagnosed with TB, may therefore have 
been symptomatic for substantial periods of time. A lack of mobility may thus 
reflect the effects of TB disease itself (i.e., be subject to reverse causality), which 
could counterbalance any increased TB risk that might be associated with 
increased mobility; a similar relationship has been suggested for HIV (33). 
Prospective data collection may help clarify these causal relationships between 
mobility and risk of disease. Additionally, our population of patients seeking TB 
diagnostic services at urban health facilities may not represent the general 
population and therefore our definition of mobility may not be appropriate for 
other populations.  
 
Conclusion 
We developed a data-driven definition of mobility among patients seeking 
care at health facilities in Kampala, Uganda. While we found no association 
between this definition of mobility and delays in TB diagnostic evaluations or risk 
of TB disease, mobile populations remain critical to infectious disease control. 
Additional research to better measure and classify mobility is warranted to 
understand the drivers of mobility in order to mitigate any increased risk that for 
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Tables and Figures 




Where were you born? 
in Kampala vs. 
outside Kampala 
n/a 
How long have you lived within 3km 
of your current residence? 
new residents: < 1 
year  
n/a 
Is there another place that you stay, 
other than the residence you have 
just described? 
yes vs. no n/a 
How often do you typically visit each 
of the following places* for any 
reason?  
Visit any taxi park at 
least 1 time per 
month vs. less than 
1 time per month 
n/a 
How often do you go somewhere 
more than about 3km from your 
residence? 
<9 times per month 
vs. ≥9 times per 
month (median) 
<2 times per 
month vs. ≥2 times 
per month (25th 
percentile) 
 
<24 times per 
month vs. ≥24 
times per month 
(75th percentile) 
When you go more than about 3km 
from your residence, how many 
hours do you usually spend >3km 
away? 
<6 hours per trip vs. 
≥6 hours per trip 
(median) 
<4 hours per trip 




<9 hours per trip 
vs. ≥9 hours per 
trip (75th 
percentile) 
How many times did you travel 
outside of Kampala in the past 12 
months, to your best recollection? 
0 trips in the last 
year vs. ≥1 trip in the 
last year 
n/a 










Table 3.2. Mobility and Sociodemographic and Risk Factor Characteristics 








 N (%) N (%)  
Mobility Characteristics    
Born in Kampala 
15 
(15%) 26 (139%) 0.63 
Lived in neighborhood <1 year 
12 
(12%) 47 (23%) 0.02 
Have another residence 8 (8%) 19 (9%) 0.67 
Visited taxi stage ≥1 times per week 
27 
(27%) 47 (23%) 0.51 
Travel 3km ≥9 times per month (median) 
50 
(50%) 101 (50%) 0.94 
Spend ≥6 hours away when traveling 3km (median) 
52 
(52%) 107 (53%) 0.81 
Ever traveled outside Kampala in last year  
73 
(72%) 156 (77%) 0.34 
Other Sociodemographic Characteristics    
Age in years   0.17 
   15-24 
19 
(19%) 44 (22%)  
   25-34 
46 
(46%) 67 (33%)  
   35-44 
22 
(22%) 48 (24%)  
   ≥45 
14 
(14%) 43 (21%)  
Female sex 
39 
(39%) 121 (60%) <0.001 
Parish of Residence   0.75 
   Kisugu 
14 
(14%) 36 (18%)  
   Wabigalo 9 (9%) 18 (9%)  
   Bukasa (within study area) 
22 
(22%) 36 (18%)  
   Other (Kisugu health Center Only) 
56 
(54%) 112 (55%)  
Location of Birth   0.76 
   Kampala 
15 
(15%) 26 (13%)  
   Northern Uganda 
10 
(10%) 17 (8%)  
   Eastern Uganda 
25 
(25%) 41 (20%)  
   Western Uganda 
20 
(20%) 40 (20%)  





   Outside Uganda 2 (2%) 9 (5%)  
Literacy   0.46 
   Can read/write without difficulty 
45 
(45%) 81 (40%)  
   Difficulty or in ability in reading/writing 
56 
(55%) 121 (60%)  
Highest completed education   0.37 
   None 
43 
(43%) 72 (36%)  
   Certificate 
52 
(52%) 110 (55%)  
   Degree/further studies 6 (6%) 20 (10%)  
Occupation   0.14 
   Employed 
74 
(73%) 142 (70%)  
   Unemployed 
23 
(23%) 39 (19%)  
   Other 4 (4%) 21 (10%)  
Income quartile   0.69 
   1st  (lowest) 
30 
(30%) 61 (30%)  
   2nd   
17 
(17%) 45 (22%)  
   3rd  
32 
(32%) 57 (28%)  
   4th (highest) 
22 
(22%) 39 (19%)  
Ever Been to Prison 
46 
(46%) 47 (23%) <0.001 
HIV Positive 
34 
(34%) 61 (30%) 0.54 
Previous TB Treatment 
26 
(26%) 21 (10%) <0.001 
Ever had household TB contact 
21 
(21%) 42 (21%) 0.98 
Ever known a TB case 
24 
(24%) 57 (28%) 0.44 





Limitations in any of the EQ-5D domains 
76 
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Table 3.3. Association of sociodemographic characteristics with mobility 
classification  
















 N (%) N (%)  N (%) N (%)  
Age in years   0.059   0.35 
   15-24 7 (11%) 12 (31%)  26 (20%) 18 (26%)  
   25-34 28 (45%) 18 (46%)  47 (36%) 20 (29%)  
   35-44 16 (26%) 6 (15%)  28 (21%) 20 (29%)  
   ≥45 11 (18%) 3 (8%)  31 (24%) 12 (17%)  
Female Sex 15 (24%) 24 (62%) <0.001 69 (52%) 52 (74%) 0.002 
Parish of Residence   0.016   0.25 
   Kisugu 11 (18%) 3 (8%)  23 (17%) 13 (19%)  
   Wabigalo 9 (15%) 0 (0%)  11 (8%) 7 (10%)  
   Bukasa (within study area) 13 (21%) 9 (23%)  19 (14%) 17 (24%)  
   Other (Kisugu health Center 
Only) 29 (47%) 27 (69%)  79 (60%) 33 (47%)  
Location of Birth   0.78   0.8 
   Kampala 9 (15%) 6 (15%)  19 (14%) 7 (10%)  
   Northern Uganda 6 (10%) 4 (10%)  13 (10%) 4 (6%)  
   Eastern Uganda 17 (27%) 8 (21%)  25 (19%) 16 (23%)  
   Western Uganda 14 (23%) 6 (15%)  26 (20%) 14 (20%)  
   Central Uganda (outside 
Kampala) 15 (24%) 14 (36%)  44 (33%) 25 (36%)  
   Outside Uganda 1 (2%) 1 (3%)  5 (4%) 4 (6%)  
Literacy   0.54   0.004 
   Can read/write without 
difficulty  26 (42%) 19 (49%)  43 (33%) 38 (54%)  
   Difficulty or in ability in 
reading/writing 36 (58%) 20 (51%)  89 (67%) 32 (46%)  
Highest completed 
education   0.2   0.018 
   None 22 (35%) 21 (54%)  39 (30%) 33 (47%)  
   Certificate 36 (58%) 16 (41%)  76 (58%) 34 (49%)  
   Degree/further studies 4 (6%) 2 (5%)  17 (13%) 3 (4%)  
Occupation   <0.001   0.011 
   Employed 54 (87%) 20 (51%)  
102 
(77%) 40 (57%)  
   Unemployed 7 (11%) 16 (41%)  19 (14%) 20 (29%)  
   Other 1 (2%) 3 (8%)  11 (8%) 10 (14%)  
Income quartile   0.19   0.1 
   1st (lowest) 15 (24%) 15 (38%)  35 (27%) 26 (37%)  
   2nd  9 (15%) 8 (21%)  26 (20%) 19 (27%)  
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   3rd  21 (34%) 11 (28%)  41 (31%) 16 (23%)  
   4th (highest) 17 (27%) 5 (13%)  30 (23%) 9 (13%)  
Ever Been to Prison 31 (50%) 15 (38%) 0.26 31 (24%) 16 (23%) 0.92 
HIV Positive 20 (32%) 14 (36%) 0.71 41 (31%) 20 (29%) 0.71 
Previous TB Treatment 16 (26%) 10 (26%) 0.99 12 (9%) 9 (13%) 0.4 
Ever had household TB 
contact 15 (24%) 6 (16%) 0.35 21 (16%) 21 (30%) 0.019 
Ever known a TB case 17 (28%) 7 (18%) 0.26 31 (24%) 26 (37%) 0.04 
Household has >=3 people 23 (37%) 15 (38%) 0.89 71 (54%) 39 (56%) 0.79 
Limitation in any of the EQ-
5D domains 41 (66%) 35 (90%) 0.007 70 (53%) 46(66%) 0.083 
 
Table 3.4. Association of mobility and sociodemographic and clinical risk 








Mobility 0.85 (0.52, 1.4) 0.85 (0.44, 1.6) 
Age in years   
   15-24 Reference Reference 
   25-34 1.6 (0.83, 3.1) 0.75 (0.31, 1.8) 
   35-44 1.1 (0.51, 2.2) 0.49 (0.17, 1.4) 
   ≥45 0.75 (0.34, 1.7) 0.39 (0.14, 1.1) 
Female Sex 0.42 (0.26, 0.69) 0.40 (0.20, 0.78) 
Parish of Residence   
   Kisugu Reference  
   Wabigalo 1.3 (0.47, 3.5)  
   Bukasa (within study area) 1.6 (0.7, 3.6)  
   Other (Kisugu health Center Only) 1.3 (0.64, 2.6)  
Location of Birth   
   Kampala Reference  
   Northern Uganda 1.0 (0.37, 2.8)  
   Eastern Uganda 1.0 (0.47, 2.4)  
   Western Uganda 0.87 (0.38, 2.0)  
   Central Uganda (outside Kampala) 0.73 (0.34, 1.6)  
   Outside Uganda 0.39 (0.07, 2.0)  
Literacy   
   Read/write no difficulty 1.2 (0.74, 2.0)  
   Can't read/write or do w/difficult Reference  
Highest completed education   
   None Reference  
   Certificate 0.79 (0.48, 1.3)  
   Degree/further studies 0.5 (0.19, 1.4)  
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Occupation   
   Employed Reference Reference 
   Unemployed 1.1 (0.63, 2.0) 1.4 (0.6, 3.0) 
   Other 0.37 (0.12, 1.1) 0.34 (0.08, 1.4) 
Income quartile   
   1st (lowest) Reference  
   2nd  0.77 (0.38, 1.6)  
   3rd  1.1 (0.62, 2.1)  
   4th (highest) 1.2 (0.58, 2.3)  
Ever Been to Prison 2.8 (1.7, 4.6) 1.7 (0.87, 3.2) 
HIV Positive 1.2 (0.70, 2.0)  
Previous TB Treatment 3.0 (1.6, 5.6) 2.8 (1.3, 5.9) 
Ever had household TB contact 1.0 (0.56, 1.8)  
Ever known a TB case 0.80 (0.46, 1.4)  
Household has >=3 people 0.50 (0.31, 0.82) 0.67 (0.37, 1.2) 
Limitation in any of the EQ-5D 










Classes df AIC BIC 
    
1 7 2247.703 2273.699 
2 15 2174.194 2229.9 
3 22 2173.285 2254.987 
4 30 2179.721 2291.133 
 
 
Table 3.S2. Marginal Probabilities for Latent Classes  
Class Probability 
1 0.42 (0.24-0.62) 
2 0.58 (0.38-0.76) 
 
 






































Table 3.S3. Marginal Means for Latent Classes of Mobility (with 95% 
Confidence Intervals) 
 Class 1 Class 2 Total* 






neighborhood < 1 











Visited taxi stage ≥1 





Travel 3km ≥9 times 





Spend ≥6 hours 
away when traveling 





Ever traveled outside 
Kampala in the last 











Table 3.S4. Marginal Means for Latent Classes of Mobility Mobility (with 
95% Confidence Intervals) - sensitivity analysis (different cutoffs for 
frequency & duration of travel) 
 
 25th percentile 75th percentile 
 Class 1 Class 2 Class 1 Class 2 Total 
Born in 










































stage ≥1 time 












Travel 3km ≥9 
times per 
month 










≥3km 0.18 (0.05-0.45) 
0.8 
(0.69-


























Figure 3.S2. Marginal Means for Latent Classes of Mobility – sensitivity 
analysis (different cutoffs for frequency & duration of travel) 
a. 25th percentile 
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Table 3.S5. Duration of TB-related symptoms among mobile vs. non-mobile 
patients (median, IQR) 
 Mobile Non-mobile p-value 
 (median, IQR) (median, IQR)  
Cases 8 (3, 16) 8 (4, 12) 0.7 
Controls 3 (2, 8) 4 (2, 8)  0.6 
 
Table 3.S6. Number of symptom-related health care visits among mobile vs. 
non-mobile patients 
 Mobile Non-mobile p-value 
 (median, IQR) (median, IQR)  
Cases 4 (3, 7) 4 (2, 7) 0.42 












Chapter 4: Is Distance associated with Tuberculosis Treatment Outcomes? A 






Introduction: Barriers to accessing nearby health facilities may hinder initiating and 
completing tuberculosis (TB) treatment. We aimed to evaluate whether distance from 
residence to health facility chosen for treatment is associated with TB treatment 
outcomes. 
Methods: We conducted a retrospective cohort study of all patients initiating TB 
treatment at six health facilities in Kampala from 2014-2016. We investigated 
associations between distance to treating facility and unfavorable TB treatment 
outcomes (death, loss to follow up, or treatment failure) using multivariable Poisson 
regression. 
Results: Unfavorable treatment outcomes occurred in 20% (339/1,691) of TB patients. 
The adjusted relative risk (aRR) for unfavorable treatment outcomes (compared to 
treatment success) was 0.87 (95% confidence interval [CI] 0.70, 1.07) for patients living 
≥ 2 km from the facility compared to those living closer. When we separately compared 
each type of unfavorable treatment outcome to favorable outcomes, those living ≥2 km 
from the facility had increased risk of death (aRR 1.42 [95%CI 0.99, 2.03]) but 
decreased risk for loss to follow-up (aRR 0.57 [95%CI 0.41, 0.78]) than those living 
within 2 km. 
Conclusions: Distance from home residence to TB treatment facility is associated with 
increased risk of death but decreased risk of loss to follow up. Those who seek care 
further from home may have advanced disease, but once enrolled may be more likely to 




Although tuberculosis (TB) is both preventable and treatable, it is the leading 
cause of death due to a single pathogen worldwide (1). One challenge in TB control is 
maintaining adherence to a minimum of six months of treatment. The World Health 
Organization estimates that 82% of patients worldwide who start treatment for TB 
experience treatment success (defined as treatment completion or cure); this 
percentage has not improved substantively in the past decade (1). People with 
restricted access to health care may not be able to initiate and complete TB treatment 
as recommended. Risk factors for unfavorable treatment outcomes include 
demographic, clinical, and health systems characteristics (2–4). 
Geographic barriers to care, including physical distance to a health facility, may 
contribute to poor treatment outcomes. Distance from home to health facility has been 
associated with decreased access to a wide range of health services and outcomes, 
including poor HIV treatment clinic attendance (5) and antiretroviral adherence (6), 
lower likelihood of facility-based childbirth (7), and maternal (8) and child mortality (9). 
Geographic barriers to care have been linked to delays (6,10), loss-to follow up (11), 
and lack of adherence during the TB diagnostic evaluation and treatment processes 
(10). Whether these associations translate into worse treatment outcomes remains 
uncertain. As the effect of geographic barriers has primarily been noted in rural areas 
where patients likely have limited options as to where they seek care and even the 
closest health care facilities may require more than an hour of travel, we aimed to 
understand the effect of these barriers on TB treatment outcomes in the context of a 
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densely populated, urban setting where there are many TB treatment facilities available 
and patients may choose to seek care at facilities other than the ones closest to them.  
Understanding links between geographic barriers to care and TB treatment 
outcomes may help identify a population at risk for unfavorable treatment outcomes that 
could be targeted with interventions to reduce barriers to care and improve outcomes. 
We therefore sought to characterize the association of distance from home to health 
facility and TB treatment outcomes in six public and private health facilities in Makindye 
division, Kampala district, Uganda. 
 
Study population and Methods 
Study Overview and Population 
We conducted a retrospective cohort study of TB patients at one public (Kisugu 
Health Center, the primary public TB treatment facility in this area) and five private 
urban outpatient health facilities serving the population of Kisugu and Wabigalo 
parishes of Makindye division, Kampala, Uganda. Facilities were included if they 
provided TB care to an average of at least one patient per month from Kisugu or 
Wabigalo parish. At each of the selected facilities, all patients initiating TB treatment 
from January 1, 2014 to December 31, 2016 and who lived in Uganda were included. 
The National TB Control Program oversees all TB care and patients may seek 
treatment at any facility of their choosing. Treatment of adult TB is largely decentralized 
in Uganda; TB cases requiring hospitalization or advanced clinical care, such as 
pediatric TB or drug-resistant TB, may be diagnosed at these facilities in the community 
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but are referred to referral hospitals for their treatment and management and would not 
be included in this analysis. All facilities providing TB treatment in Uganda are expected 
to follow the national guidelines for TB treatment, although variation in implementation 
may exist and additional services (such as laboratory tests) may incur additional 
charges at private facilities. In urban settings, the national guidelines recommend that 
patients or their treatment supporters report to the treating facility to receive their anti-
TB drugs every two weeks during the intensive phase and every four weeks during the 
continuation phase. 
 
Data Collection  
Demographic and clinical data were abstracted retrospectively from the Facility 
TB Registers, including treatment facility, parish of residence, age at diagnosis, sex, 
HIV status, site of disease (pulmonary vs. extrapulmonary), treatment regimen, 
diagnostic test results (sputum microscopy and Xpert MTB/RIF [Cepheid, Inc., 
Sunnyvale, California, USA]), date of treatment initiation, and treatment outcome. Data 
were abstracted directly as written in the registers with guidance from health facility staff 
as needed. Study data were collected and managed using REDCap (Research 





Measurement of Primary Exposure and Outcome 
We used reported area of residence to calculate two measures of distance from 
residence to the health facility where the patient chose to receive TB treatment. The TB 
registers do not capture patient addresses but do have information on the administrative 
area of residence, the smallest of which is the parish with a median size of 0.13 km2 
and median population of 23,041 within Kampala. The centroid of the parish of 
residence was used to estimate each patient’s location of residence based on parish 
boundaries provided by Uganda Bureau of Statistics 2014 census data. We calculated 
Euclidean distance as a straight line from parish centroid to each health facility using 
ArcGIS (ESRI, Redlands, California, USA). Additionally, we used OpenStreetMap 
(OpenStreetMap Foundation, Cambridge, United Kingdom) to define road networks and 
calculated travel distance based on the shortest available route using the Network 
Analysis tool in ArcGIS.  
Treatment outcomes following the World Health Organization (WHO) definitions 
were abstracted from the Facility TB Registers. “Unfavorable” outcomes included 
treatment failure, death, and loss to follow-up (including those with a documented 
outcome of default); patients with no documented outcome were not included in the 
analysis, although we performed a sensitivity analysis in which these patients were 
considered to have unfavorable outcomes. These were compared to favorable 
treatment outcomes of treatment completion or cure (also called treatment success). 
Patients with an outcome of “transferred out” (with no additional treatment outcome 




Facility TB Notification Rate  
We calculated an average annual “facility TB notification rate” for each parish, 
which we defined as the annual average number of cases from the parish reported at 
the six facilities divided by the parish’s 2014 population from the Uganda Bureau of 
Statistics (14). We used Poisson regression to assess the association of Euclidean 
distance from the parish centroid to the facility where the patients received TB treatment 
on facility TB notification rates.  
 
Distance to TB treatment facility and Treatment Outcomes 
To measure the association between distance from residence to TB treatment 
facility and treatment outcome at the individual level, our primary exposure was 
Euclidean distance divided into four categories: <2 km, 2 to <5 km, 5 to <10 km, and 
≥10 km. These categories were chosen based on the following rationale: <2 km is 
walking distance and therefore distance should not represent significant barriers to care; 
2 to <5 km is still quite close but may require additional means of transport or additional 
travel time; 5 to <10 km is within the urban area but may take significant time and/or 
resources to travel; ≥10 km represents a significant investment in time and resources to 
reach the facility. For additional analyses using shortest available route travel distance, 
we used the same four distance categories. We also considered a binary exposure with 
distance dichotomized as <2 km or ≥2 km. Our outcome of interest was unfavorable 
treatment outcome, which was defined as above.  
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Patient characteristics were compared across the four exposure categories for 
Euclidean distance using chi-square tests. Risk factors of interest were defined a priori 
as characteristics known to be associated with TB treatment outcomes and that 
conceivably could lead to differences in care-seeking behavior and choice of TB 
treatment facility, and included: age, sex, HIV status, site of disease (pulmonary vs. 
extrapulmonary), lack of bacteriologic confirmation (positive sputum microscopy or 
GeneXpert), year of treatment, and treatment facility. We estimated the relative risk as a 
measure of association between unfavorable treatment outcomes and Euclidean 
distance, modeling distance both in four categories (with reference to the <2 km 
category) and as binary, using simple and multivariable Poisson regression with robust 
variance. All risk factors of interest were included in the multivariable model regardless 
of statistical significance. We analyzed associations between travel distance and 
unfavorable treatment outcomes in similar fashion. In a sub-analysis, we also analyzed 





From 2014 to 2016, 2,251 patients initiated TB treatment at the six study 
facilities, of whom 2,146 (95.3%) had a documented residential information in the 
Facility TB register. Patients came from 181 parishes in 28 districts throughout Uganda. 
We excluded 261 (12.2%) patients whose listed parish of residence information could 
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not be matched to a parish listed in the 2014 Uganda Bureau of Statistics Census and 
an additional 16 participants from analyses of travel distance who could not be linked 
due to lack of road network connectivity. We excluded 109 (5.8%) TB patients who were 
transferred out as we were unable to determine their final treatment outcome. Among 
1,691 patients with reported outcomes, favorable treatment outcomes were seen in 
1,352 (80.0%) of TB patients; 85 (4.8%) TB patients had no documented treatment. 
 
Facility TB Notification Rate  
Average annual parish-level facility TB notification rates ranged from 0 to 327 TB 
cases per 100,000 population (Figure 1). Facility notification rates decreased by 4% 
with each additional kilometer from the parish centroid to the health facility where the 
patient received TB treatment (rate ratio 0.96 [95% CI 0.95, 0.97]).  
 
Distance to TB treatment facility and Treatment Outcomes 
The median Euclidean distance from the centroid of parish of residence to health 
facility where the patient chose to receive TB treatment was 3.7 km. While many 
patients lived <2 km from their chosen facility (34%), nearly half of patients lived 2-10 
km from their facility (49%), and 17% lived ≥ 10 km from their facility. Across the four 
distance exposure groups, there were differences in age, sex, HIV status, disease site, 
laboratory confirmation of disease, year of treatment initiation, and health facility (all 
p<0.05) (Table 1). People living ≥2km from the facility were more likely to be female 
(42% vs 34%), HIV positive (53% vs 46%), have extrapulmonary disease (17% vs. 8%), 
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and lack bacteriologic confirmation of disease (37% vs. 24%) compared to those living 
<2 km from the facility. 
In simple and multivariable Poisson regression models, no significant association 
was seen between the four categories of distance and unfavorable treatment outcomes 
(Table 2). In analysis of a binary measure of distance, the adjusted relative risk [aRR] 
for unfavorable treatment outcomes was 0.87 (95% CI 0.70, 1.07) for patients who lived 
≥2 km from the facility where they chose to receive TB treatment compared to those 
living within 2 km. Patients who were HIV positive (aRR 1.72 [95%CI 1.36, 2.17]), over 
the age of 65 years (aRR 2.53 [95%CI 1.59, 4.04]), or lacked bacteriologic confirmation 
of TB (aRR 1.57 [95%CI 1.27, 1.94]) were more likely to have unfavorable treatment 
outcomes. Patients aged less than 14 years (aRR 0.44 [95%CI 0.21, 0.90]) or receiving 
TB treatment at St. Francis Nsambya Hospital (aRR 0.60 [95%CI 0.45, 0.80], compared 
to Kisugu Health Centre) had lower risk of unfavorable treatment outcomes. 
In a sub-analysis evaluating death and loss to follow-up separately, distances of 
≥ 2 km from residence to facility chosen for TB treatment were associated with an 
increased risk of death but decreased risk of loss to follow up (Table 3). Comparing 
those living ≥2 km from the facility to those living within 2 km, the adjusted RR for death 
was 1.42 (95% CI 0.99, 2.03) and the adjusted RR for loss to follow up was 0.57 (95% 
CI 0.41, 0.78). Risk factors for death included older age (55-64 years or 65+ years), 




Travel distance  
Travel distance using the shortest available route was strongly correlated with 
Euclidean distance (R2=0.98) but was on average 19% further than Euclidean distance 
(95% CI 18%, 20%). While 31.1% of participants were reclassified to a different 
distance category if travel distance was used instead of Euclidean distance, there were 
no substantive differences in the association between distance from facility chosen for 
TB treatment and treatment outcomes when using travel distance as the exposure 
compared to Euclidean distance (Tables in supplement).  
 
Discussion 
This analysis of 1,774 patients treated for TB across six urban clinics in the 
Makindye division of Kampala, Uganda, was suggestive of a protective association 
between longer distance from home to chosen treatment facility and composite 
unfavorable treatment outcomes. Facility notification rates for the included treatment 
facilities were high in parishes nearest to the facilities but were also high for some 
parishes far from the facilities. Nevertheless, despite the high density of TB treatment 
facilities in Kampala, 66% of patients starting TB treatment in these six facilities lived 
more than ≥2 km from the treating facilities (Table 1); compared to those who lived 
within 2 km of the facility, those living more remotely were 42% more likely to die but 
43% less likely to be lost to follow-up. 
Most patients in our study setting live within 2 km of multiple facilities and 
therefore can choose where they want to receive TB care. Patients may choose to seek 
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care at a facility further away due to stigma against TB and a desire to hide their TB 
status (15–17), convenience due to work or other travel (18), or perception of better 
care, particularly at private facilities (18). This dynamic may explain the differences seen 
when considering death versus loss to follow up as an outcome. Death during TB 
treatment in this setting (where multidrug resistance is uncommon) likely reflects a 
patient’s severity of illness when diagnosed, whereas loss to follow-up may more 
closely reflect patient motivation and health system investment. Thus, patients who 
choose to travel more than 2 km to be treated may be those who experience other 
barriers to seeking care (e.g., stigma, job-related time limitations, unease with the 
healthcare system) which can cause delays in diagnosis and treatment. Such delays 
are associated with increased disease severity (19) and higher corresponding mortality 
rates (20–22). However, once treatment is initiated, these patients who are sicker and 
willing to travel longer distances may be more motivated to adhere to treatment, thereby 
reducing losses to follow-up. These findings illustrate how important distinctions 
between these two outcomes may be obscured when considering unfavorable treatment 
outcome as a composite measure. 
Our study fills an important gap in knowledge regarding barriers to care and TB 
treatment outcomes. Prior studies have had mixed results regarding the effect of 
distance on delays in TB diagnosis and initiation of TB treatment (2–4). Our study 
suggests that, once treatment is initiated, distance is not associated with overall 
unfavorable treatment outcomes. Other studies have highlighted economic, socio-
cultural, and health system barriers to care in high-burden settings as access-related 
risk factors for poor treatment outcomes (23); the current research suggests that 
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geographic distance to treatment facility may not be a strong measure of access to 
care, particularly in the urban sub-Saharan African setting. Additionally, our finding that 
travel distance using the shortest available route does not change our results compared 
to using Euclidean distance is in contrast with other research (24). This may reflect the 
high population density and informal road network in our setting, such that travel paths 
are generally direct and the differences between Euclidean and travel distances are 
small, particularly if walking or using boda bodas (motorbike taxis) for transport. 
This analysis does have some key limitations, largely due to the limited data 
available in facility TB registers. For example, these registers do not contain data on 
precise address of residence, thus limiting our measurement of distance to that of the 
parish centroid. Nevertheless, on average, participants will live within 500 meters of the 
parish centroid, making major bias at the scale of our distance categories less likely. 
Additionally, while Euclidean distance does not directly capture the distance traveled to 
seek care, our assessment of travel distance yielded comparable results. Due to the 
limited data available in the TB registers, we are unable to assess the contribution of 
broader barriers to health care access, including economic, socio-cultural, and health 
system barriers. These factors may overlap or interact with geographic barriers. 
Additionally, we could not assess patients’ reasons for choosing particular facilities; 
further qualitative research could help to elucidate these motivations. Our study includes 
patients attending facilities in a densely crowded urban area, and our findings may not 
generalize to other settings (e.g., rural areas) where facilities are further apart and 
patients have fewer treatment options. While we do not have complete capture of any 
geographic region (e.g., people living in Kisugu and Wabigalo parishes) due to our 
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sampling frame based on health facilities, we do have full capture of every patient 
seeking care at these facilities. Our final models excluded more than 20% of TB cases 
seen at these facilities due to missing data on either residence or treatment outcome; 
while our sensitivity analysis showed no major effect of excluding those missing 
treatment outcomes, we may have selection bias if those included in our analysis are 
not representative of those missing residential information in regards to the association 
of distance on treatment outcomes. Finally, since we only considered patients enrolled 




Distance from home residence to TB treatment facility was not associated with 
overall unfavorable treatment outcomes in this urban Ugandan population, but was 
associated with increased risk of death and decreased risk of loss to follow up. These 
findings suggest that those who seek care further from home may do so at a more 
advanced disease state, but once enrolled they may be more likely to remain in 
treatment. This is important for TB control programs to consider, as they may need to 
invest in programs that decrease delays in diagnosis among those living further away 
and improving treatment adherence among those who live closer to facilities. A detailed 
understanding of the patient population and the varying experiences of that population 
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Tables and Figures 
Table 4.1. Patient characteristics by distance from residence to TB health facility 
 
Total 
Euclidean Distance Categories 
p-value 
< 2km 





≥ 10 km 














          <0.001 
0-14  87 (5) 21 (3) 20 (4) 26 (6) 20 (7)   
15-24 366 (21) 142 
(23) 
95 (21) 81 (20) 48 (16)   






86 (29)   




93 (23) 70 (23)   
45-54 200 (11) 66 (11) 37 (8) 48 (12) 49 (16)   
55-64 61 (3) 21 (3) 12 (3) 11 (3) 17 (6)   
≥65 35 (2) 10 (2) 4 (1) 7 (2) 14 (5)   













































Year of treatment 
initiation (N=1,773) 1 
          0.289 















89 (30)   









Facility (N=1,776)           <0.001 





84 (18) 51 (13) 22 (7)   




55 (14) 67 (22)   
International Hospital 
Kampala 
178 (10) 92 (15) 27 (6) 37 (9) 22 (7)   
Kibuli Muslim Hospital 184 (10) 49 (8) 28 (6) 63 (15) 44 (14)   
St. Francis Hospital - 
Nsambya 










Meeting Point 12 (1) 9 (2) 2 (0) 0 (0) 1 (0)   
Treatment Outcome 
(N=1,776) 
          <0.001 















97 (32)   
Failure 21 (1) 4 (1) 9 (2) 7 (2) 1 (0)   
Died 167 (9) 38 (6) 48 (10) 44 (11) 37 (12)   
Lost to Follow Up 
(including Default) 
151 (9) 88 (15) 29 (6) 22 (5) 12 (4)  
Unknown/Missing 85 (5) 33 (5) 26 (6) 13 (3) 13 (4)   





Table 4.2. Crude and Adjusted Relative Risks for unfavorable TB treatment 






Euclidean Distance     
<2 km Reference Reference 
2 to <5 km 0.88 (0.69, 1.12) 0.91 (0.70, 1.17) 
5 to <10 km 0.82 (0.63, 1.06) 0.88 (0.68, 1.15) 
>10 km 0.76 (0.56, 1.02) 0.77 (0.57, 1.04) 
Age at diagnosis     
0-14 years 0.42 (0.20, 0.87) 0.44 (0.21, 0.90) 
15-24 years 0.63 (0.46, 0.87) 0.79 (0.57, 1.08) 
25-34 years Reference Reference 
35-44 years 1.03 (0.80, 1.32) 0.97 (0.75, 1.25) 
45-54 years 1.35 (1.02, 1.77) 1.18 (0.89, 1.57) 
55-64 years 1.25 (0.79, 1.98) 1.23 (0.79, 1.92) 
>65 years 1.96 (1.25, 3.06) 2.53 (1.59, 4.04) 
Male sex 1.12 (0.92, 1.36) 1.08 (0.88, 1.32) 
HIV Positive 1.83 (1.50, 2.24) 1.72 (1.36, 2.17) 
Pulmonary TB 0.85 (0.66, 1.10) 1.06 (0.80, 1.40) 
Lack of bacteriologic 
confirmation 1.47 (1.22, 1.78) 1.57 (1.27, 1.94) 
Treatment Start year     
2014 Reference Reference 
2015 0.89 (0.71, 1.12) 0.88 (0.70, 1.11) 
2016 0.86 (0.69, 1.09) 0.89 (0.71, 1.11) 
Facility     
Kisugu Health Center 
(public) Reference Reference 




Kampala 0.99 (0.70, 1.40) 0.84 (0.59, 1.20) 
Kibuli Muslim Hospital 1.01 (0.72, 1.40) 0.97 (0.70, 1.35) 
St. Francis Hospital - 
Nsambya 0.63 (0.48, 0.83) 0.60 (0.45, 0.80) 






Table 4.3. Adjusted relative risks for Death and Loss to Follow up during TB 
treatment 






Euclidean Distance     
    <2 km Reference Reference 
    2 to <5 km 1.48 (0.99, 2.22) 0.59 (0.38, 0.89) 
    5 to <10 km 1.38 (0.90, 2.12) 0.61 (0.39, 0.95) 
    >10 km 1.35 (0.86, 2.10) 0.45 (0.25, 0.81) 
Age at diagnosis     
    0-14 years 0.59 (0.24, 1.46) 0.28 (0.07, 1.12) 
    15-24 years 0.59 (0.30, 1.14) 0.80 (0.53, 1.22) 
    25-34 years Reference Reference 
    35-44 years 1.38 (0.94, 2.02) 0.65 (0.42, 0.99) 
    45-54 years 1.68 (1.11, 2.54) 0.64 (0.36, 1.12) 
    55-64 years 2.08 (1.23, 3.51) 0.51 (0.16, 1.58) 
    >65 years 6.44 (3.69, 11.27) 0.77 (0.20, 3.02) 
Male sex 0.98 (0.74, 1.31) 1.31 (0.94, 1.83) 
HIV Positive 3.28 (2.23, 4.81) 1.05 (0.73, 1.51) 
Pulmonary TB 0.93 (0.66, 1.30) 1.50 (0.78, 2.86) 
Lack of bacteriological 
confirmation 2.14 (1.59, 2.89) 1.45 (0.99, 2.13) 
Treatment Start year     
    2014 Reference Reference 
    2015 0.78 (0.55, 1.10) 0.88 (0.61, 1.26) 
    2016 0.81 (0.59, 1.13) 0.88 (0.61, 1.27) 
Facility     
    Kisugu Health Center 
(public) Reference Reference 
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    Alive Medical Services 1.02 (0.63, 1.66) 1.10 (0.74, 1.62) 
    International Hospital 
Kampala 1.41 (0.83, 2.39) 0.60 (0.34, 1.08) 
    Kibuli Muslim Hospital 1.48 (0.90, 2.44) 0.83 (0.49, 1.41) 
    St. Francis Hospital - 
Nsambya 0.92 (0.59, 1.45) 0.25 (0.14, 0.46) 
    Meeting Point 1.72 (0.51, 5.77) excluded 





Figure 4.1. TB Facility Notification by Parish in Kampala District1 and surrounding 
areas for six Facilities serving Kisugu and Wabigalo Parishes2, 2014-2016  
a. Annual Facility Notification Rate per 100,000 population (based on 2014 
census) 
b. Total Count of Facility Notified TB Cases 
 
 
1 Parishes further outside Kampala not displayed. Dark line indicates Kampala District 
boundary 
2 Facility Notification Rates and Total Number of TB Cases Reported are from six study 
facilities providing TB treatment and do not represent all TB cases diagnosed at all 




Figure 4.2. Percentage of TB Cases with unfavorable treatment outcomes by 
Parish in Kampala District and surrounding areas, 2014-2016  
 
Note: Parishes further outside Kampala not displayed. Dark line indicates Kampala 







Table 4.S1 Adjusted relative risks for unfavorable TB treatment outcomes using 
Euclidean and travel distance 
  Euclidean Distance Travel Distance 
  Adjusted RR (95% CI) Adjusted RR (95% CI) 
Distance     
<2 km Reference Reference 
2 to <5 km 0.91 (0.70, 1.17) 0.94 (0.70, 1.26) 
5 to <10 km 0.88 (0.68, 1.15) 0.96 (0.71, 1.31) 
>10 km 0.77 (0.57, 1.04) 0.79 (0.56, 1.10) 
Age at diagnosis     
0-14 years 0.44 (0.21, 0.90) 0.44 (0.21, 0.91) 
15-24 years 0.79 (0.57, 1.08) 0.79 (0.57, 1.09) 
25-34 years Reference Reference 
35-44 years 0.97 (0.75, 1.25) 0.97 (0.75, 1.25) 
45-54 years 1.18 (0.89, 1.57) 1.19 (0.90, 1.59) 
55-64 years 1.23 (0.79, 1.92) 1.25 (0.80, 1.95) 
>65 years 2.53 (1.59, 4.04) 2.54 (1.59, 4.04) 
Male 1.08 (0.88, 1.32) 1.09 (0.89, 1.33) 
HIV Positive 1.72 (1.36, 2.17) 1.71 (1.35, 2.16) 
Pulmonary TB 1.06 (0.80, 1.40) 1.05 (0.79, 1.39) 
Lack of bacteriological 
confirmation 1.57 (1.27, 1.94) 1.58 (1.28, 1.95) 
Treatment Start year     
2014 Reference Reference 
2015 0.88 (0.70, 1.11) 0.89 (0.71, 1.12) 
2016 0.89 (0.71, 1.11) 0.89 (0.71, 1.12) 
Facility     
Kisugu Health Center (public) Reference Reference 
Alive Medical Services 0.97 (0.74, 1.27) 0.94 (0.72, 1.23) 
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International Hospital Kampala 0.84 (0.59, 1.20) 0.84 (0.59, 1.20) 
Kibuli Muslim Hospital 0.97 (0.70, 1.35) 0.93 (0.67, 1.30) 
St. Francis Hospital - Nsambya 0.60 (0.45, 0.80) 0.57 (0.43, 0.75) 






Table 4.S2. Sensitivity Analysis comparing adjusted relative risks for unfavorable 
TB treatment outcomes including and excluding patients with no documented 
outcomes 
  Unfavorable Outcomes 
Unfavorable + Unknown 
Outcomes 
  Adjusted RR (95% CI) Adjusted RR (95% CI) 
Euclidean Distance     
<2 km Reference Reference 
2 to<5 km 0.91 (0.70, 1.17) 0.94 (0.78, 1.14) 
5 to <10 km 0.88 (0.68, 1.15) 0.90 (0.73, 1.10) 
>10 km 0.77 (0.57, 1.04) 0.90 (0.72, 1.12) 
Age at diagnosis     
0-14 years 0.44 (0.21, 0.90) 0.69 (0.45, 1.05) 
15-24 years 0.79 (0.57, 1.08) 0.90 (0.72, 1.13) 
25-34 years Reference Reference 
35-44 years 0.97 (0.75, 1.25) 0.96 (0.80, 1.17) 
45-54 years 1.18 (0.89, 1.57) 1.06 (0.85, 1.33) 
55-64 years 1.23 (0.79, 1.92) 1.11 (0.78, 1.59) 
>65 years 2.53 (1.59, 4.04) 1.93 (1.31, 2.83) 
Male 1.08 (0.88, 1.32) 1.09 (0.94, 1.26) 
HIV Positive 1.72 (1.36, 2.17) 1.40 (1.18, 1.66) 
Pulmonary TB 1.06 (0.80, 1.40) 1.01 (0.82, 1.24) 
Lack of bacteriological 
confirmation 1.57 (1.27, 1.94) 1.56 (1.33, 1.84) 
Treatment Start year     
2014 Reference Reference 
2015 0.88 (0.70, 1.11) 0.94 (0.78, 1.12) 
2016 0.89 (0.71, 1.11) 1.04 (0.88, 1.23) 
Facility     
Kisugu Health Center Reference Reference 
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Alive Medical Services 0.97 (0.74, 1.27) 1.09 (0.89, 1.33) 
International Hospital 0.84 (0.59, 1.20) 1.15 (0.91, 1.45) 
Kibuli Muslim Hospital 0.97 (0.70, 1.35) 0.96 (0.75, 1.24) 
St. Francis Hospital - 
Nsambya 0.60 (0.45, 0.80) 0.51 (0.40, 0.65) 





Table 4.S3. Adjusted relative risks for unfavorable TB treatment outcomes 
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Summary of Key Findings 
In order to achieve the End TB vision of a world free of TB (1), there need 
to be substantial improvements to the efficiency and implementation of current 
TB control interventions. This research used the application of spatiotemporal 
epidemiology in the context of local TB epidemics to investigate approaches to 
improving TB control methods in urban, high-burden settings.  
In aim 1, we used routinely collected data and small-scale administrative 
units to assess the potential yield of targeted, community based active case 
finding interventions. We demonstrated that even within a very small area (2.2 
km2) where access to care is expected to be homogeneous, there is substantial 
heterogeneity in the spatial distribution of TB cases presenting at the local health 
facilities such that more than 60% of cases come from areas accounting for only 
20% of the population. Additionally, through a subsequent active case finding 
activity, we showed that the facility-based TB notifications reasonably predict the 
location of undiagnosed TB in the community; more than 40% of cases found 
during our community-based case finding intervention came from those same 
areas accounting for 20% of the population. Therefore, in this setting it may be 
feasible to detect nearly half of undiagnosed TB cases in the community by 
targeted case finding interventions to only 20% of the population. Additionally, 
the application of these methods may be useful in other urban, high-burden 
settings.  
In aim 2, we investigated geographic mobility, which complements aim 1 
by considering the potential TB risk that occurs way from one’s home residence. 
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Using six a priori defined questions regarding routine movement beyond the 
study boundaries, we developed a definition of geographic mobility using latent 
class analysis. We found that frequency and duration of travel more than 3 km 
from home were the driving components of this case definition. However, we 
found no association between this definition of mobility and TB case status 
(compared to TB negative controls) (adjusted odds ratio 0.85 [95% CI 0.44-1.6]) 
or between mobility and delays in TB diagnosis among TB cases (p>0.05). This 
is one of the first attempts to characterize mobility in the context of TB; further 
research should address other potential measures and causes of mobility in 
order to develop a better understanding of mobility that can be used more 
broadly to identify potential risk groups for TB or other diseases. 
In aim 3, we used a broader study population to assess the association of 
distance between home residence and TB treatment facility and unfavorable TB 
treatment outcomes. We found that patients residing further from the facility 
where they received their care were more likely to die before completing 
treatment (adjusted risk ratio [aRR] 1.42 (95% CI 0.99-2.03) but less likely to be 
lost to follow-up (aRR 0.57 [95% CI 0.41-0.79]). This suggests that patients who 
live further away from the health facility may delay seeking care, and thus have 
more advanced disease leading to increased mortality, but that once patients 
from further away are engaged in care they are more invested and less likely to 
be lost to follow-up.  
 These aims together demonstrate that spatiotemporal epidemiology, 
including location of residence and movement behavior occurring outside that 
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residence, is an important consideration for TB control programs. In aim 1, we 
show that using small-scale administrative area of residence to target active case 
finding may efficiently identify undiagnosed cases in the community. However, 
the impact may be limited if those case finding activities fail to capture the mobile 
individuals identified in aim 2, who may not be home during door-to-door testing. 
Similarly, if those cases identified reside too far from a health facility to receive 
timely treatment and are at increased risk of mortality as shown in aim 3, the 
effect of the case finding on treatment outcomes may be minimal. Incorporating 
spatiotemporal epidemiology is an important consideration in the development of 
targeted TB interventions.  
 
Public health implications 
This research was designed to not only to advance understanding of 
geography and movement as it relates to TB, but also to directly inform TB 
control in this setting in urban Uganda and to inform approaches to 
understanding local spatiotemporal epidemiology of TB in other settings. For 
example, from our results in aim 1, we can recommend that this study area 
implement case finding activities in areas with high TB facility-based notification 
rates; we can also recommend that other areas consider a similar approach to 
identifying high-risk locations based on their own data. We can also suggest that 
our study facilities consider TB treatment adherence interventions that focus on 
reducing loss to follow-up among people living close to the facility, who may be 
less invested in their care, based on the results from aim 3; facilities in other 
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settings could replicate our analysis using their own treatment data to see if their 
patient population is at similar risk for loss to follow-up.  
A major strength of this research is its hyper-local context. While there is 
increasing interest in applying spatial approaches to TB research and control 
programs, this is generally done at the national or district level (2). Research at 
this geographic level can give broad context to the epidemic but cannot inform 
locally appropriate interventions. Therefore, there is a need for high-quality 
routinely collected spatiotemporal data at the local level. This includes improved 
quality of GIS data as well as improved timeliness and accessibility in order to 
detect areas with high burden or limited healthcare access in an actionable 
timeframe (3). Supplementing health system data with additional data sources, 
such as Open Street Map (4), can support more complex analyses of the 
relationship between geography and health (5,6). Given the sensitive nature of 
spatiotemporal data, as more data becomes available considerations regarding 
maintaining confidentiality will become increasingly important (7–9). 
We present one of the first attempts to investigate geographic mobility at 
the individual level among people at risk for TB; previous research has focused 
on using population-level mobility in transmission models for TB and other 
infectious diseases (10–13). The importance of this mobility in relation to 
infectious disease transmission is increasingly recognized; for example, Uganda 
is currently implementing control measures for Ebola due to the outbreak in 
bordering Democratic Republic of Congo (14) and is applying new methods to 
collecting data on population movement in order to plan those efforts. As better 
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data collection tools and measures of mobility are developed, these should be 
applied across disease programs to supplement spatial analyses based on 
residence, particularly in scenarios where transmission is likely to occur outside 
the home.   
 
Limitations 
We posit the role of location in TB risk as being a combination of local 
transmission and local barriers to care. In this research, we are not able to 
distinguish the causes for associations seen between location and TB. For 
example, in Aim 1 we identified areas with high TB notification rates and 
undiagnosed TB, but we could not determine whether there in ongoing 
transmission or if these cases represent recent reactivation or undiagnosed 
active TB. However, by framing our approach from the perspective of 
implementing active case finding interventions, we were able to show potential 
impact of such interventions without explicitly understand the cause of the local 
epidemic. Molecular sequencing technologies are rarely used in this type of 
setting but could help understand transmission (15). 
Fixing the “delivery gap” (16) in TB between effective interventions and the 
highest-need is only one piece of the solution to the TB epidemic. Models 
suggest that in high-burden settings, even broad scale-up of a single intervention 
will not be sufficient to reach the End TB targets; in some settings, even scale-up 
of all the major interventions would not achieve these goals (17). While, 
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improvement in the implementation of established TB interventions (18) will 
contribute to these goals, this needs to be done in parallel with additional 
research on preventive vaccines, therapeutic solutions to latent TB infection, 
rapid point of care diagnostics, and shorter drug regimens (18) in order to end 
the TB epidemic. 
 
Conclusions 
Despite substantial investments and efforts, the annual reduction in TB 
incidence is too slow to meet the End TB targets (18). Interventions targeted at 
established high-risk populations have shown effectiveness and efficiency; the 
incorporation of spatiotemporal risk factors in defining and identifying high-risk 
populations may improve TB control efforts. Using detailed local epidemiology, 
we describe how the location of residence as well as movement outside that 
residence play a role in TB risk and access to care in an urban, high-burden 
setting. Further understanding of these risk factors in this setting as well as 
others is critical to targeting TB control interventions to high-risk populations that 
are being missed by current practices and to reduce the global incidence of TB 
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